PKN2
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| O14617 | S658 | Sugiyama | AP3D1 PRO0039 | DERPRAVFHEEEQRRPKHRPsEADEEELARRREARKQEQAN |
| O14974 | S910 | Sugiyama | PPP1R12A MBS MYPT1 | yETssTsAGDRyDsLLGRsGsysYLEERKPYSSRLEKDDST |
| O15553 | S208 | SIGNOR|EPSD|PSP | MEFV MEF TRIM20 | PGPCRALEGGQAEVRLRRNAssAGRLQGLAGGAPGQKECRP |
| O15553 | S242 | SIGNOR|EPSD|PSP | MEFV MEF TRIM20 | GQKECRPFEVYLPSGKMRPRsLEVTISTGEKAPANPEILLT |
| O60814 | S37 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| O76021 | S314 | Sugiyama | RSL1D1 CATX11 CSIG PBK1 L12 | RNFEKQKERKKKRQQARKtAsVLsKDDVAPEsGDtTVKKPE |
| O95678 | S162 | Sugiyama | KRT75 K6HF KB18 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| O95835 | S464 | Sugiyama | LATS1 WARTS | SPSSGHEIPTWQPNIPVRsNsFNNPLGNRASHSANSQPSAT |
| P02538 | S176 | Sugiyama | KRT6A K6A KRT6D | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWT |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04259 | S176 | Sugiyama | KRT6B K6B KRTL1 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05455 | S94 | Sugiyama | SSB | KSKAELMEIsEDKTKIRRsPsKPLPEVTDEyKNDVKNRsVY |
| P05787 | S104 | Sugiyama | KRT8 CYK8 | IQAVRTQEKEQIKTLNNKFAsFIDKVRFLEQQNKMLETKWS |
| P07814 | S335 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PIEKNLQMWEEMKKGsQFGQsCCLRAKIDMSSNNGCMRDPt |
| P08729 | S104 | Sugiyama | KRT7 SCL | LQRVRQEESEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWT |
| P09132 | S69 | Sugiyama | SRP19 | IQDVCSAVGLNVFLEKNKMYsREWNRDVQYRGRVRVQLKQE |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P12035 | S211 | Sugiyama | KRT3 | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWN |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13639 | S38 | Sugiyama | EEF2 EF2 | NIRNMsVIAHVDHGKStLtDsLVCKAGIIAsARAGEtRFtD |
| P13647 | S181 | Sugiyama | KRT5 | IQRVRTEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P15880 | S190 | Sugiyama | RPS2 RPS4 | WGNKIGKPHTVPCKVTGRCGsVLVRLIPAPRGtGIVsAPVP |
| P22059 | S193 | Sugiyama | OSBP OSBP1 | VTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNTLRT |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P23246 | S283 | Sugiyama | SFPQ PSF | GPGGRsEEKIsDsEGFKANLsLLRRPGEKTyTQRCRLFVGN |
| P24534 | S141 | Sugiyama | EEF1B2 EEF1B EF1B | ERLAQYESKKAKKPALVAKssILLDVKPWDDEtDMAKLEEC |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P29474 | S1179 | GPS6|PSP | NOS3 | IFGLTLRTQEVTSRIRtQsFsLQERQLRGAVPWAFDPPGSD |
| P32969 | S182 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | QQATTVKNKDIRKFLDGIyVsEKGtVQQADE__________ |
| P35908 | S191 | Sugiyama | KRT2 KRT2A KRT2E | IQNVKAQEREQIKTLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| P38646 | T116 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | DGERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKD |
| P38646 | Y118 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | ERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIK |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P48668 | S176 | Sugiyama | KRT6C KRT6E | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P53396 | S457 | Sugiyama | ACLY | FLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMPQD |
| P57053 | S37 | Sugiyama | H2BC12L H2BFS H2BS1 | KAVTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P58876 | S37 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61313 | Y6 | Sugiyama | RPL15 EC45 TCBAP0781 | _______________MGAYKyIQELWRKKQSDVMRFLLRVR |
| P62263 | S139 | Sugiyama | RPS14 PRO2640 | LARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL________ |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62807 | S37 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | KAVTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIss |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62906 | T9 | Sugiyama | RPL10A NEDD6 | ____________MSSKVsRDtLyEAVREVLHGNQRKRRKFL |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P84098 | S122 | Sugiyama | RPL19 | LRRLLRRYRESKKIDRHMyHsLyLKVKGNVFKNKRILMEHI |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q01546 | S196 | Sugiyama | KRT76 KRT2B KRT2P | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWE |
| Q14153 | S167 | Sugiyama | FAM53B KIAA0140 SMP | YsGGsVQRYSNGFSTMQRsssFSLPSRANVLssPCDQAGLH |
| Q14CN4 | S138 | Sugiyama | KRT72 K6IRS2 KB35 KRT6 KRT6IRS2 | IQRVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWN |
| Q16513 | S183 | Sugiyama | PKN2 PRK2 PRKCL2 | sNGSsKDRKLHGtAQQLLQDsKTKIEVIRMQILQAVQTNEL |
| Q16513 | S360 | Sugiyama | PKN2 PRK2 PRKCL2 | DILENVPGRSKATSVALPGWsPsEtRssFMsRTSKSKSGSS |
| Q16513 | S362 | Sugiyama | PKN2 PRK2 PRKCL2 | LENVPGRSKATSVALPGWsPsEtRssFMsRTSKSKSGSSRN |
| Q16513 | S37 | Sugiyama | PKN2 PRK2 PRKCL2 | GDsRsLPFSENVsAVQKLDFsDtMVQQKLDDIKDRIKREIR |
| Q16513 | S370 | Sugiyama | PKN2 PRK2 PRKCL2 | KATSVALPGWsPsEtRssFMsRTSKSKSGSSRNLLKTDDLS |
| Q16513 | S582 | Sugiyama | PKN2 PRK2 PRKCL2 | tVTKLDFDLEPEPPPAPPRAssLGEIDEssELRVLDIPGQD |
| Q16513 | S583 | Sugiyama | PKN2 PRK2 PRKCL2 | VTKLDFDLEPEPPPAPPRAssLGEIDEssELRVLDIPGQDs |
| Q16513 | S590 | Sugiyama | PKN2 PRK2 PRKCL2 | LEPEPPPAPPRAssLGEIDEssELRVLDIPGQDsEtVFDIQ |
| Q16513 | S603 | Sugiyama | PKN2 PRK2 PRKCL2 | sLGEIDEssELRVLDIPGQDsEtVFDIQNDRNsILPKsQsE |
| Q16513 | S615 | Sugiyama | PKN2 PRK2 PRKCL2 | VLDIPGQDsEtVFDIQNDRNsILPKsQsEyKPDtPQsGLEy |
| Q16513 | S631 | Sugiyama | PKN2 PRK2 PRKCL2 | NDRNsILPKsQsEyKPDtPQsGLEysGIQELEDRRSQQRFQ |
| Q16513 | S636 | Sugiyama | PKN2 PRK2 PRKCL2 | ILPKsQsEyKPDtPQsGLEysGIQELEDRRSQQRFQFNLQD |
| Q16513 | T121 | Sugiyama | PKN2 PRK2 PRKCL2 | QELNAHIVVsDPEDItDCPRtPDtPNNDPRCSTSNNRLKAL |
| Q16513 | T124 | Sugiyama | PKN2 PRK2 PRKCL2 | NAHIVVsDPEDItDCPRtPDtPNNDPRCSTSNNRLKALQKQ |
| Q16513 | T175 | Sugiyama | PKN2 PRK2 PRKCL2 | AENMIQMYsNGSsKDRKLHGtAQQLLQDsKTKIEVIRMQIL |
| Q16513 | T364 | Sugiyama | PKN2 PRK2 PRKCL2 | NVPGRSKATSVALPGWsPsEtRssFMsRTSKSKSGSSRNLL |
| Q16513 | T39 | Sugiyama | PKN2 PRK2 PRKCL2 | sRsLPFSENVsAVQKLDFsDtMVQQKLDDIKDRIKREIRKE |
| Q16513 | T628 | Sugiyama | PKN2 PRK2 PRKCL2 | DIQNDRNsILPKsQsEyKPDtPQsGLEysGIQELEDRRSQQ |
| Q16513 | T958 | Sugiyama | PKN2 PRK2 PRKCL2 | RGREDVSNFDDEFtsEAPILtPPREPRILsEEEQEMFRDFD |
| Q16513 | Y624 | Sugiyama | PKN2 PRK2 PRKCL2 | EtVFDIQNDRNsILPKsQsEyKPDtPQsGLEysGIQELEDR |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q3SY84 | S143 | Sugiyama | KRT71 K6IRS1 KB34 KRT6IRS1 | IQKVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q5QNW6 | S37 | Sugiyama | H2BC18 HIST2H2BF | KAVTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q5SYE7 | S1495 | Sugiyama | NHSL1 C6orf63 KIAA1357 | KNRRAQEEWAKNEGLMPRsLsFsGPRYGRSRTPPSAASSRY |
| Q5XKE5 | S155 | Sugiyama | KRT79 K6L KB38 KRT6L | IQRVRTQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q7RTS7 | S153 | Sugiyama | KRT74 K6IRS4 KB37 KRT5C KRT6IRS4 | IQKVRAQEREQIKVLNDKFAsFIDKVRFLEQQNQVLETKWE |
| Q7Z417 | S652 | Sugiyama | NUFIP2 KIAA1321 PIG1 | NtLLGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsI |
| Q7Z794 | S177 | Sugiyama | KRT77 KRT1B | IQRIKTQEREQIMVLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86Y46 | S145 | Sugiyama | KRT73 K6IRS3 KB36 KRT6IRS3 | IQKVRAQEREQIKVLNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q8IWX8 | S904 | Sugiyama | CHERP DAN26 SCAF6 | KGVGVALDDPyENyRRNKsysFIARMKARDECK________ |
| Q8IZ21 | S590 | Sugiyama | PHACTR4 PRO2963 | SKEEWNEIRHQIGNTLIRRLsQRPtPEELEQRNILQPKNEA |
| Q8NBJ7 | S256 | Sugiyama | SUMF2 PSEC0171 UNQ1968/PRO4500 | EWTASPYQAAEQDMRVLRGAsWIDtADGsANHRARVttRMG |
| Q93079 | S37 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99848 | S270 | Sugiyama | EBNA1BP2 EBP2 | FGGKKKGSKWNtREsyDDVssFRAKTAHGRGLKRPGKKGSN |
| Q99877 | S37 | Sugiyama | H2BC15 H2BFD HIST1H2BN | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99879 | S37 | Sugiyama | H2BC14 H2BFE HIST1H2BM | KAINKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99880 | S37 | Sugiyama | H2BC13 H2BFC HIST1H2BL | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q9BX95 | S112 | Sugiyama | SGPP1 SPP1 | GLAAELGPAsPRRAGALRRNsLtGEEGQLARVSNWPLYCLF |
| Q9BX95 | T114 | Sugiyama | SGPP1 SPP1 | AAELGPAsPRRAGALRRNsLtGEEGQLARVSNWPLYCLFCF |
| Q9H788 | S315 | Sugiyama | SH2D4A PPP1R38 SH2A | LNSGAYPQKPLRNQGVVRtLsssAQEDIIRWFKEEQLPLRA |
| Q9NR19 | S30 | Sugiyama | ACSS2 ACAS2 | sGsGSRGQEEAGAGGRARsWsPPPEVsRSAHVPSLQRYREL |
| Q9NSB2 | S178 | Sugiyama | KRT84 KRTHB4 | AQRVKKDEKEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWS |
| Q9UKV8 | S387 | Sugiyama | AGO2 EIF2C2 | ATARSAPDRQEEISKLMRsAsFNTDPyVREFGIMVKDEMTD |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Signal Transduction | R-HSA-162582 | 2.584599e-13 | 12.588 | 1 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.333356e-12 | 11.632 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.724897e-10 | 9.429 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 8.045067e-10 | 9.094 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.109205e-09 | 8.955 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.325163e-09 | 8.364 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 5.027946e-09 | 8.299 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.435116e-09 | 8.129 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.142743e-08 | 7.942 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.910711e-08 | 7.719 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.113617e-08 | 7.675 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.587198e-08 | 7.587 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.506868e-08 | 7.455 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 3.352973e-08 | 7.475 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.386572e-08 | 7.470 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 3.506868e-08 | 7.455 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 3.783457e-08 | 7.422 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.940607e-08 | 7.404 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.076694e-08 | 7.216 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.999055e-08 | 7.222 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.022976e-08 | 7.153 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 7.430212e-08 | 7.129 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.354591e-07 | 6.868 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.539013e-07 | 6.813 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.539013e-07 | 6.813 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.487394e-07 | 6.828 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.590729e-07 | 6.798 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.832881e-07 | 6.737 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.208152e-07 | 6.656 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.208152e-07 | 6.656 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.149668e-07 | 6.668 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.459914e-07 | 6.609 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 2.477601e-07 | 6.606 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.666642e-07 | 6.574 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.191418e-07 | 6.496 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.388079e-07 | 6.470 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.101495e-07 | 6.387 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.247065e-07 | 6.280 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.261255e-07 | 6.203 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 6.252760e-07 | 6.204 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 7.728523e-07 | 6.112 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.728523e-07 | 6.112 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 8.017804e-07 | 6.096 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 9.109128e-07 | 6.041 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.010253e-06 | 5.996 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.095956e-06 | 5.960 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.177788e-06 | 5.929 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.182746e-06 | 5.927 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.227288e-06 | 5.911 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.438613e-06 | 5.842 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.584214e-06 | 5.800 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.715616e-06 | 5.766 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.851107e-06 | 5.733 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.028714e-06 | 5.693 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.028714e-06 | 5.693 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.167317e-06 | 5.664 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 2.162993e-06 | 5.665 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.405024e-06 | 5.619 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.924521e-06 | 5.534 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.551990e-06 | 5.450 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 3.934927e-06 | 5.405 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.944710e-06 | 5.404 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.944710e-06 | 5.404 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.488668e-06 | 5.188 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 6.626526e-06 | 5.179 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 7.095940e-06 | 5.149 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 8.553335e-06 | 5.068 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 9.016209e-06 | 5.045 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.092847e-05 | 4.961 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.296305e-05 | 4.887 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.617705e-05 | 4.791 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.780905e-05 | 4.749 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.780905e-05 | 4.749 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.869767e-05 | 4.728 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.410448e-05 | 4.618 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.563984e-05 | 4.591 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.058065e-05 | 4.515 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.044057e-05 | 4.517 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 3.781576e-05 | 4.422 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.084018e-05 | 4.389 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 5.175633e-05 | 4.286 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.294553e-05 | 4.276 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 6.795970e-05 | 4.168 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 6.874695e-05 | 4.163 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 7.068346e-05 | 4.151 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 7.069614e-05 | 4.151 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 8.394921e-05 | 4.076 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 8.394921e-05 | 4.076 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 9.212292e-05 | 4.036 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.008022e-04 | 3.997 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.047623e-04 | 3.980 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.081106e-04 | 3.966 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.097954e-04 | 3.959 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.107560e-04 | 3.956 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.161396e-04 | 3.935 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.159736e-04 | 3.936 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.159736e-04 | 3.936 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.149095e-04 | 3.940 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.419668e-04 | 3.848 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.514997e-04 | 3.820 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 1.515339e-04 | 3.819 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.596927e-04 | 3.797 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.671338e-04 | 3.777 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.804586e-04 | 3.744 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.961740e-04 | 3.707 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.983819e-04 | 3.702 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.986735e-04 | 3.702 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.986735e-04 | 3.702 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.177006e-04 | 3.662 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.217709e-04 | 3.654 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.373717e-04 | 3.625 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.796988e-04 | 3.553 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.174508e-04 | 3.498 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.104858e-04 | 3.508 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.194691e-04 | 3.496 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.385751e-04 | 3.470 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.385751e-04 | 3.470 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.385751e-04 | 3.470 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 3.393132e-04 | 3.469 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.491609e-04 | 3.457 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.608856e-04 | 3.443 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.682419e-04 | 3.434 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.891249e-04 | 3.410 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.989020e-04 | 3.399 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.300212e-04 | 3.367 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 4.826340e-04 | 3.316 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.920632e-04 | 3.308 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.081045e-04 | 3.294 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.081045e-04 | 3.294 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 5.263805e-04 | 3.279 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.407622e-04 | 3.267 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 6.633093e-04 | 3.178 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 7.634764e-04 | 3.117 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 8.327856e-04 | 3.079 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.547922e-04 | 3.068 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.187667e-04 | 3.037 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 9.299598e-04 | 3.032 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 9.903657e-04 | 3.004 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.077072e-03 | 2.968 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.326247e-03 | 2.877 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.363589e-03 | 2.865 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.579580e-03 | 2.801 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.743539e-03 | 2.759 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.859598e-03 | 2.731 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.910310e-03 | 2.719 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.851268e-03 | 2.733 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 1.933567e-03 | 2.714 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.092300e-03 | 2.679 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.097742e-03 | 2.678 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.122166e-03 | 2.673 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.122166e-03 | 2.673 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.201220e-03 | 2.657 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.442835e-03 | 2.612 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.510242e-03 | 2.600 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.656787e-03 | 2.576 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.075610e-03 | 2.512 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.075610e-03 | 2.512 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.206104e-03 | 2.494 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 3.505561e-03 | 2.455 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.729858e-03 | 2.428 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 4.048888e-03 | 2.393 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.145201e-03 | 2.382 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.262116e-03 | 2.370 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 4.539555e-03 | 2.343 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.641112e-03 | 2.333 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.682757e-03 | 2.329 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.713884e-03 | 2.327 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.883147e-03 | 2.311 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 5.444809e-03 | 2.264 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 5.280291e-03 | 2.277 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.004269e-03 | 2.301 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 4.903645e-03 | 2.309 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 5.059381e-03 | 2.296 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.429428e-03 | 2.265 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 5.607948e-03 | 2.251 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 5.607948e-03 | 2.251 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.209259e-03 | 2.207 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 6.470379e-03 | 2.189 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 7.091950e-03 | 2.149 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 7.313110e-03 | 2.136 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 7.313110e-03 | 2.136 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 7.601960e-03 | 2.119 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 7.775050e-03 | 2.109 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 7.806520e-03 | 2.108 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 7.871764e-03 | 2.104 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 8.013625e-03 | 2.096 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 8.059367e-03 | 2.094 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 8.132411e-03 | 2.090 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 8.613947e-03 | 2.065 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 8.613947e-03 | 2.065 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 8.613947e-03 | 2.065 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 8.613947e-03 | 2.065 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 9.054353e-03 | 2.043 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 9.207712e-03 | 2.036 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 8.944071e-03 | 2.048 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 8.944071e-03 | 2.048 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 8.713452e-03 | 2.060 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.237892e-03 | 2.034 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 9.321493e-03 | 2.031 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 9.636610e-03 | 2.016 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.022018e-02 | 1.991 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.061012e-02 | 1.974 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.083914e-02 | 1.965 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.107655e-02 | 1.956 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.107655e-02 | 1.956 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.129254e-02 | 1.947 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.138458e-02 | 1.944 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.139429e-02 | 1.943 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.177582e-02 | 1.929 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.211401e-02 | 1.917 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 1.229851e-02 | 1.910 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.229851e-02 | 1.910 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.268661e-02 | 1.897 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.313778e-02 | 1.881 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.313778e-02 | 1.881 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 1.441517e-02 | 1.841 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.400522e-02 | 1.854 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.402445e-02 | 1.853 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.402445e-02 | 1.853 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.402445e-02 | 1.853 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.402445e-02 | 1.853 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.532091e-02 | 1.815 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.542395e-02 | 1.812 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.605703e-02 | 1.794 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.605703e-02 | 1.794 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.605703e-02 | 1.794 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.605703e-02 | 1.794 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.605703e-02 | 1.794 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.636941e-02 | 1.786 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.710070e-02 | 1.767 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.797139e-02 | 1.745 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.849015e-02 | 1.733 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.901611e-02 | 1.721 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.918044e-02 | 1.717 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 2.045034e-02 | 1.689 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.088350e-02 | 1.680 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 2.088350e-02 | 1.680 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 2.197097e-02 | 1.658 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.207872e-02 | 1.656 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 2.222529e-02 | 1.653 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.222529e-02 | 1.653 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 2.222529e-02 | 1.653 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.222529e-02 | 1.653 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 2.222529e-02 | 1.653 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 2.287292e-02 | 1.641 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.498537e-02 | 1.602 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.496788e-02 | 1.603 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 2.577714e-02 | 1.589 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.234036e-02 | 1.651 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.577714e-02 | 1.589 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.302007e-02 | 1.638 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.409734e-02 | 1.618 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.222529e-02 | 1.653 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.643157e-02 | 1.578 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 2.686561e-02 | 1.571 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 2.686561e-02 | 1.571 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.790210e-02 | 1.554 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.814764e-02 | 1.551 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.816495e-02 | 1.550 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.845598e-02 | 1.546 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.900587e-02 | 1.538 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.900587e-02 | 1.538 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.900587e-02 | 1.538 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.900587e-02 | 1.538 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.900587e-02 | 1.538 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.900587e-02 | 1.538 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.916303e-02 | 1.535 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.953801e-02 | 1.530 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.003112e-02 | 1.522 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 3.003112e-02 | 1.522 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 3.141536e-02 | 1.503 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.159009e-02 | 1.500 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.159009e-02 | 1.500 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 3.219232e-02 | 1.492 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 3.219232e-02 | 1.492 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.394980e-02 | 1.469 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.397897e-02 | 1.469 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.407501e-02 | 1.468 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.407501e-02 | 1.468 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.439453e-02 | 1.464 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.446183e-02 | 1.463 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 4.165070e-02 | 1.380 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.629746e-02 | 1.440 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.629746e-02 | 1.440 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.590526e-02 | 1.445 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 4.162266e-02 | 1.381 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.629746e-02 | 1.440 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.629746e-02 | 1.440 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.590526e-02 | 1.445 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 3.920655e-02 | 1.407 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.590526e-02 | 1.445 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 3.732507e-02 | 1.428 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 3.599119e-02 | 1.444 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 4.162266e-02 | 1.381 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 4.178316e-02 | 1.379 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.101079e-02 | 1.387 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.880726e-02 | 1.411 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 4.336083e-02 | 1.363 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 4.375906e-02 | 1.359 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 4.412842e-02 | 1.355 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 4.439320e-02 | 1.353 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 4.439320e-02 | 1.353 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 4.473614e-02 | 1.349 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.667086e-02 | 1.331 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 4.744199e-02 | 1.324 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 4.887988e-02 | 1.311 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 4.893081e-02 | 1.310 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.974694e-02 | 1.303 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 4.991548e-02 | 1.302 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 4.991548e-02 | 1.302 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 5.050637e-02 | 1.297 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 5.092428e-02 | 1.293 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 5.092428e-02 | 1.293 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 5.439230e-02 | 1.264 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 5.533468e-02 | 1.257 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 5.533468e-02 | 1.257 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 5.563119e-02 | 1.255 | 1 | 0 |
| Cardiac conduction | R-HSA-5576891 | 5.570148e-02 | 1.254 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 5.732536e-02 | 1.242 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 5.786995e-02 | 1.238 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 5.860943e-02 | 1.232 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 5.883909e-02 | 1.230 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 5.883909e-02 | 1.230 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 5.994234e-02 | 1.222 | 0 | 0 |
| Transport of glycerol from adipocytes to the liver by Aquaporins | R-HSA-432030 | 5.994234e-02 | 1.222 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 5.994234e-02 | 1.222 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 5.994234e-02 | 1.222 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 6.217849e-02 | 1.206 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 6.217849e-02 | 1.206 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 6.217849e-02 | 1.206 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 6.217849e-02 | 1.206 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 6.217849e-02 | 1.206 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 6.302498e-02 | 1.200 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 6.395427e-02 | 1.194 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.492134e-02 | 1.188 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 6.604840e-02 | 1.180 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 6.604840e-02 | 1.180 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 6.604840e-02 | 1.180 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 6.604840e-02 | 1.180 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 6.604840e-02 | 1.180 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 6.727668e-02 | 1.172 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 6.727668e-02 | 1.172 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.772374e-02 | 1.169 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.548286e-02 | 1.122 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.548286e-02 | 1.122 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.548286e-02 | 1.122 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 7.548286e-02 | 1.122 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.874753e-02 | 1.163 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 7.336328e-02 | 1.135 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 8.566104e-02 | 1.067 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.967175e-02 | 1.099 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 7.548286e-02 | 1.122 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 7.548286e-02 | 1.122 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 7.612882e-02 | 1.118 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 7.598904e-02 | 1.119 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 7.865178e-02 | 1.104 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 7.624521e-02 | 1.118 | 1 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 7.360501e-02 | 1.133 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 7.360501e-02 | 1.133 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 8.589160e-02 | 1.066 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 6.928315e-02 | 1.159 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 7.336328e-02 | 1.135 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 7.274944e-02 | 1.138 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 7.598904e-02 | 1.119 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 8.652934e-02 | 1.063 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 8.898748e-02 | 1.051 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 8.982089e-02 | 1.047 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 8.982089e-02 | 1.047 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 8.982089e-02 | 1.047 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 9.131537e-02 | 1.039 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 9.131537e-02 | 1.039 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 9.131537e-02 | 1.039 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 9.131537e-02 | 1.039 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 9.154307e-02 | 1.038 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 9.380031e-02 | 1.028 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.380031e-02 | 1.028 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 9.422786e-02 | 1.026 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 9.422786e-02 | 1.026 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 9.422786e-02 | 1.026 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 9.456084e-02 | 1.024 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 9.587301e-02 | 1.018 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.587301e-02 | 1.018 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 9.587301e-02 | 1.018 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 9.604418e-02 | 1.018 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 9.797404e-02 | 1.009 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 9.797404e-02 | 1.009 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 9.797404e-02 | 1.009 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 9.872673e-02 | 1.006 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.988148e-02 | 1.001 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 9.988148e-02 | 1.001 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.026319e-01 | 0.989 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.043486e-01 | 0.982 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.230857e-01 | 0.910 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.230857e-01 | 0.910 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.230857e-01 | 0.910 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.230857e-01 | 0.910 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.230857e-01 | 0.910 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.230857e-01 | 0.910 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.230857e-01 | 0.910 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.230857e-01 | 0.910 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.230857e-01 | 0.910 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.230857e-01 | 0.910 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.230857e-01 | 0.910 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.230857e-01 | 0.910 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.408873e-01 | 0.851 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.408873e-01 | 0.851 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.408873e-01 | 0.851 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.408873e-01 | 0.851 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.408873e-01 | 0.851 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 1.408873e-01 | 0.851 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.166007e-01 | 0.933 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.149370e-01 | 0.940 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.149370e-01 | 0.940 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.149370e-01 | 0.940 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.149370e-01 | 0.940 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.081029e-01 | 0.966 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.081029e-01 | 0.966 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.081029e-01 | 0.966 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.149937e-01 | 0.939 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.063394e-01 | 0.973 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.063394e-01 | 0.973 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 1.326680e-01 | 0.877 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.188877e-01 | 0.925 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.154381e-01 | 0.938 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.086258e-01 | 0.964 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.399494e-01 | 0.854 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.081029e-01 | 0.966 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.311829e-01 | 0.882 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.321858e-01 | 0.879 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.068860e-01 | 0.971 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.204317e-01 | 0.919 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.247943e-01 | 0.904 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.067599e-01 | 0.972 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 1.188200e-01 | 0.925 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 1.188200e-01 | 0.925 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 1.188200e-01 | 0.925 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 1.188200e-01 | 0.925 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.247943e-01 | 0.904 | 1 | 1 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.408873e-01 | 0.851 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 1.180667e-01 | 0.928 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 1.081029e-01 | 0.966 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.374419e-01 | 0.862 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.380741e-01 | 0.860 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.403954e-01 | 0.853 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.383176e-01 | 0.859 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.374419e-01 | 0.862 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.374419e-01 | 0.862 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.180667e-01 | 0.928 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 1.188200e-01 | 0.925 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.281147e-01 | 0.892 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.383113e-01 | 0.859 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.061512e-01 | 0.974 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.353119e-01 | 0.869 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.063394e-01 | 0.973 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.414532e-01 | 0.849 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.420611e-01 | 0.848 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.429934e-01 | 0.845 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.429934e-01 | 0.845 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 1.457462e-01 | 0.836 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.457462e-01 | 0.836 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 1.457462e-01 | 0.836 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 1.459396e-01 | 0.836 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.459396e-01 | 0.836 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.459396e-01 | 0.836 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 1.459396e-01 | 0.836 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.459396e-01 | 0.836 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.462085e-01 | 0.835 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 1.462085e-01 | 0.835 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.462085e-01 | 0.835 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.462085e-01 | 0.835 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.462085e-01 | 0.835 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.475095e-01 | 0.831 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.475569e-01 | 0.831 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.475569e-01 | 0.831 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.481155e-01 | 0.829 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.481155e-01 | 0.829 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.483927e-01 | 0.829 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.483927e-01 | 0.829 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.487211e-01 | 0.828 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.494230e-01 | 0.826 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.534980e-01 | 0.814 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.557048e-01 | 0.808 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.310277e-01 | 0.636 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.310277e-01 | 0.636 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.310277e-01 | 0.636 | 0 | 0 |
| Defective SLC26A4 causes Pendred syndrome (PDS) | R-HSA-5619046 | 2.310277e-01 | 0.636 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.310277e-01 | 0.636 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.310277e-01 | 0.636 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.310277e-01 | 0.636 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.310277e-01 | 0.636 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.869054e-01 | 0.728 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 1.869054e-01 | 0.728 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.869054e-01 | 0.728 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 1.869054e-01 | 0.728 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 1.869054e-01 | 0.728 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.869054e-01 | 0.728 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.869054e-01 | 0.728 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.869054e-01 | 0.728 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 1.869054e-01 | 0.728 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 1.869054e-01 | 0.728 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.869054e-01 | 0.728 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 3.256882e-01 | 0.487 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.256882e-01 | 0.487 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.256882e-01 | 0.487 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.256882e-01 | 0.487 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.256882e-01 | 0.487 | 0 | 0 |
| MPS IIID - Sanfilippo syndrome D | R-HSA-2206305 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC12A3 causes Gitelman syndrome (GS) | R-HSA-5619087 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.256882e-01 | 0.487 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.256882e-01 | 0.487 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 3.256882e-01 | 0.487 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.256882e-01 | 0.487 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.346148e-01 | 0.630 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.346148e-01 | 0.630 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.346148e-01 | 0.630 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 1.773737e-01 | 0.751 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 1.773737e-01 | 0.751 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.773737e-01 | 0.751 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.773737e-01 | 0.751 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 1.615509e-01 | 0.792 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.615509e-01 | 0.792 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 1.615509e-01 | 0.792 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.829026e-01 | 0.548 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.829026e-01 | 0.548 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 4.087008e-01 | 0.389 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 4.087008e-01 | 0.389 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 4.087008e-01 | 0.389 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 4.087008e-01 | 0.389 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 4.087008e-01 | 0.389 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 4.087008e-01 | 0.389 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.087008e-01 | 0.389 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 4.087008e-01 | 0.389 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 4.087008e-01 | 0.389 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 4.087008e-01 | 0.389 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.870573e-01 | 0.728 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.870573e-01 | 0.728 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.447124e-01 | 0.611 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 2.447124e-01 | 0.611 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 1.664049e-01 | 0.779 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.309041e-01 | 0.480 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.309041e-01 | 0.480 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 3.309041e-01 | 0.480 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.309041e-01 | 0.480 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 1.881365e-01 | 0.726 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.881365e-01 | 0.726 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 1.881365e-01 | 0.726 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 2.797676e-01 | 0.553 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.797676e-01 | 0.553 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.413982e-01 | 0.617 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 2.108166e-01 | 0.676 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.108166e-01 | 0.676 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.643655e-01 | 0.784 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.609256e-01 | 0.793 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.813684e-01 | 0.741 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 1.813684e-01 | 0.741 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.054515e-01 | 0.687 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 2.343156e-01 | 0.630 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.343156e-01 | 0.630 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.343156e-01 | 0.630 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.343156e-01 | 0.630 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.343156e-01 | 0.630 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 3.152354e-01 | 0.501 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 3.152354e-01 | 0.501 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 3.779584e-01 | 0.423 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 3.779584e-01 | 0.423 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 3.779584e-01 | 0.423 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 3.779584e-01 | 0.423 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 3.779584e-01 | 0.423 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.779584e-01 | 0.423 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.763020e-01 | 0.754 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.763020e-01 | 0.754 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 1.990696e-01 | 0.701 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 2.585010e-01 | 0.588 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.507796e-01 | 0.455 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 3.507796e-01 | 0.455 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 3.507796e-01 | 0.455 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 3.507796e-01 | 0.455 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 3.507796e-01 | 0.455 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 3.507796e-01 | 0.455 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.832400e-01 | 0.548 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 2.259803e-01 | 0.646 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.689380e-01 | 0.570 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.689380e-01 | 0.570 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.689380e-01 | 0.570 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.689380e-01 | 0.570 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.235715e-01 | 0.373 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 4.235715e-01 | 0.373 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 4.235715e-01 | 0.373 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.235715e-01 | 0.373 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 3.084011e-01 | 0.511 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.084011e-01 | 0.511 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.982103e-01 | 0.703 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.911131e-01 | 0.536 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.911131e-01 | 0.536 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.861041e-01 | 0.413 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 3.861041e-01 | 0.413 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 3.574461e-01 | 0.447 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.858921e-01 | 0.731 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.338565e-01 | 0.476 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 3.136420e-01 | 0.504 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.958790e-01 | 0.529 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.292571e-01 | 0.640 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.292571e-01 | 0.640 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.091670e-01 | 0.680 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.835144e-01 | 0.736 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.684105e-01 | 0.571 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 3.164374e-01 | 0.500 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 3.164374e-01 | 0.500 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.364341e-01 | 0.473 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 3.594826e-01 | 0.444 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 3.868515e-01 | 0.412 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.868515e-01 | 0.412 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 4.209525e-01 | 0.376 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 4.209525e-01 | 0.376 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.673854e-01 | 0.330 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.673854e-01 | 0.330 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 4.673854e-01 | 0.330 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.846151e-01 | 0.546 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.372359e-01 | 0.472 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 3.851621e-01 | 0.414 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 3.851621e-01 | 0.414 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 4.160738e-01 | 0.381 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 3.012190e-01 | 0.521 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.551066e-01 | 0.342 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.346870e-01 | 0.475 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 2.474192e-01 | 0.607 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 4.449688e-01 | 0.352 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 4.449688e-01 | 0.352 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.004094e-01 | 0.397 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.362466e-01 | 0.360 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.226198e-01 | 0.491 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.180950e-01 | 0.497 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.215145e-01 | 0.375 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.215145e-01 | 0.375 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.215145e-01 | 0.375 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 2.865183e-01 | 0.543 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 4.734084e-01 | 0.325 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 4.734084e-01 | 0.325 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 3.734965e-01 | 0.428 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.983285e-01 | 0.400 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.634402e-01 | 0.334 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 4.417515e-01 | 0.355 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.022280e-01 | 0.520 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.597524e-01 | 0.585 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.372359e-01 | 0.472 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.911131e-01 | 0.536 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.923972e-01 | 0.534 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.652467e-01 | 0.782 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.079268e-01 | 0.512 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.956322e-01 | 0.529 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 2.557556e-01 | 0.592 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.881365e-01 | 0.726 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.925775e-01 | 0.715 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 2.413982e-01 | 0.617 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.563813e-01 | 0.448 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 1.881365e-01 | 0.726 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.610711e-01 | 0.793 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 3.012190e-01 | 0.521 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.585010e-01 | 0.588 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 3.002764e-01 | 0.522 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.280170e-01 | 0.484 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.160738e-01 | 0.381 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 4.614538e-01 | 0.336 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.259921e-01 | 0.646 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.615509e-01 | 0.792 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 2.987386e-01 | 0.525 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 3.517443e-01 | 0.454 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 4.272701e-01 | 0.369 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.491703e-01 | 0.457 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 2.292571e-01 | 0.640 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 2.104443e-01 | 0.677 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.372359e-01 | 0.472 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.899548e-01 | 0.721 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.656323e-01 | 0.576 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 3.360537e-01 | 0.474 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 3.360537e-01 | 0.474 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 4.030773e-01 | 0.395 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.447124e-01 | 0.611 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 1.922988e-01 | 0.716 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 4.209525e-01 | 0.376 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 3.861938e-01 | 0.413 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.861041e-01 | 0.413 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.681042e-01 | 0.572 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 2.689380e-01 | 0.570 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 1.773737e-01 | 0.751 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 3.152354e-01 | 0.501 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 2.369404e-01 | 0.625 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 2.552027e-01 | 0.593 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.634402e-01 | 0.334 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 3.932334e-01 | 0.405 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 4.434760e-01 | 0.353 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.869054e-01 | 0.728 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 2.829026e-01 | 0.548 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 1.664049e-01 | 0.779 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 2.697990e-01 | 0.569 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.779584e-01 | 0.423 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 1.763020e-01 | 0.754 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.472083e-01 | 0.607 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.363269e-01 | 0.626 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 2.435709e-01 | 0.613 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 4.551066e-01 | 0.342 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 4.449688e-01 | 0.352 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 4.285138e-01 | 0.368 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.861938e-01 | 0.413 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.983285e-01 | 0.400 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 4.089318e-01 | 0.388 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 2.860696e-01 | 0.544 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.619980e-01 | 0.441 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.217421e-01 | 0.654 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.868515e-01 | 0.412 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.756290e-01 | 0.560 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.574461e-01 | 0.447 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 1.869054e-01 | 0.728 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 2.346148e-01 | 0.630 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 2.104443e-01 | 0.677 | 0 | 0 |
| PKA activation | R-HSA-163615 | 1.881365e-01 | 0.726 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 2.413982e-01 | 0.617 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.108166e-01 | 0.676 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 3.779584e-01 | 0.423 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 2.987386e-01 | 0.525 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.557556e-01 | 0.592 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 4.476153e-01 | 0.349 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.797676e-01 | 0.553 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 3.084011e-01 | 0.511 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.684105e-01 | 0.571 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.514832e-01 | 0.454 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.615509e-01 | 0.792 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.005721e-01 | 0.698 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.514832e-01 | 0.454 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 2.069445e-01 | 0.684 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.346870e-01 | 0.475 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.363269e-01 | 0.626 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 3.164374e-01 | 0.500 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 3.326557e-01 | 0.478 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 2.104443e-01 | 0.677 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 2.829026e-01 | 0.548 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.870573e-01 | 0.728 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.137458e-01 | 0.670 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 3.152354e-01 | 0.501 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.990696e-01 | 0.701 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 2.260159e-01 | 0.646 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 4.235715e-01 | 0.373 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 4.235715e-01 | 0.373 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 4.235715e-01 | 0.373 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 3.861041e-01 | 0.413 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.958790e-01 | 0.529 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.472656e-01 | 0.607 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.374475e-01 | 0.624 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 4.551066e-01 | 0.342 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.843318e-01 | 0.546 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 4.513627e-01 | 0.345 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 3.887636e-01 | 0.410 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.728305e-01 | 0.325 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 3.907484e-01 | 0.408 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 2.472083e-01 | 0.607 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.759000e-01 | 0.425 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.759000e-01 | 0.425 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.327670e-01 | 0.364 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 2.987386e-01 | 0.525 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 2.756290e-01 | 0.560 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 3.971596e-01 | 0.401 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 4.208562e-01 | 0.376 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.987386e-01 | 0.525 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.634811e-01 | 0.334 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.662786e-01 | 0.575 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 1.870573e-01 | 0.728 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.136420e-01 | 0.504 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.997121e-01 | 0.700 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 3.164374e-01 | 0.500 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.004909e-01 | 0.522 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.615509e-01 | 0.792 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 2.104443e-01 | 0.677 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 2.447124e-01 | 0.611 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.881365e-01 | 0.726 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.697990e-01 | 0.569 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.235715e-01 | 0.373 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.557556e-01 | 0.592 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.856253e-01 | 0.544 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 4.551066e-01 | 0.342 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.735085e-01 | 0.325 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 2.557556e-01 | 0.592 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.922988e-01 | 0.716 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.619980e-01 | 0.441 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.425433e-01 | 0.354 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 4.215145e-01 | 0.375 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 2.756290e-01 | 0.560 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.558648e-01 | 0.341 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.584114e-01 | 0.588 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 3.954842e-01 | 0.403 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.256543e-01 | 0.647 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.735085e-01 | 0.325 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.872873e-01 | 0.542 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.069445e-01 | 0.684 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.310277e-01 | 0.636 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.869054e-01 | 0.728 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.256882e-01 | 0.487 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.256882e-01 | 0.487 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 2.104443e-01 | 0.677 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 2.829026e-01 | 0.548 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.087008e-01 | 0.389 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.870573e-01 | 0.728 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 2.797676e-01 | 0.553 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.813684e-01 | 0.741 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.697990e-01 | 0.569 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.779584e-01 | 0.423 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.987386e-01 | 0.525 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.652467e-01 | 0.782 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.832400e-01 | 0.548 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 4.235715e-01 | 0.373 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 2.800012e-01 | 0.553 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 2.800012e-01 | 0.553 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.594826e-01 | 0.444 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 4.673854e-01 | 0.330 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 3.012190e-01 | 0.521 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.551066e-01 | 0.342 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.879327e-01 | 0.411 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.879327e-01 | 0.411 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.248334e-01 | 0.372 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.860860e-01 | 0.544 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.715314e-01 | 0.566 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 2.430329e-01 | 0.614 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 2.472083e-01 | 0.607 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.248334e-01 | 0.372 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.715314e-01 | 0.566 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.800012e-01 | 0.553 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.003415e-01 | 0.522 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.715314e-01 | 0.566 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.786847e-01 | 0.555 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.105775e-01 | 0.677 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.700423e-01 | 0.769 | 1 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.557556e-01 | 0.592 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 3.759000e-01 | 0.425 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.706397e-01 | 0.327 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.849173e-01 | 0.733 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 2.104443e-01 | 0.677 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 4.235715e-01 | 0.373 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 4.673854e-01 | 0.330 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.563813e-01 | 0.448 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 4.147016e-01 | 0.382 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 4.734084e-01 | 0.325 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 1.643655e-01 | 0.784 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 2.104443e-01 | 0.677 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.870573e-01 | 0.728 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.309041e-01 | 0.480 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 3.507796e-01 | 0.455 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 3.507796e-01 | 0.455 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 3.507796e-01 | 0.455 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.235715e-01 | 0.373 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.673854e-01 | 0.330 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.673854e-01 | 0.330 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 4.160738e-01 | 0.381 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.381821e-01 | 0.358 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 3.090065e-01 | 0.510 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 3.586033e-01 | 0.445 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.786695e-01 | 0.748 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 3.985971e-01 | 0.399 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 3.594011e-01 | 0.444 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.330219e-01 | 0.478 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 3.203656e-01 | 0.494 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.160738e-01 | 0.381 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.911131e-01 | 0.536 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.429532e-01 | 0.465 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.259921e-01 | 0.646 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.177891e-01 | 0.498 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.091670e-01 | 0.680 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.256882e-01 | 0.487 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.087008e-01 | 0.389 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 2.447124e-01 | 0.611 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 2.797676e-01 | 0.553 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 2.413982e-01 | 0.617 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 3.084011e-01 | 0.511 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 3.574461e-01 | 0.447 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.338565e-01 | 0.476 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 4.209525e-01 | 0.376 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 4.673854e-01 | 0.330 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 4.673854e-01 | 0.330 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 3.792867e-01 | 0.421 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.150843e-01 | 0.382 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 4.274718e-01 | 0.369 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.364341e-01 | 0.473 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.338565e-01 | 0.476 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.492220e-01 | 0.348 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.393335e-01 | 0.621 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 3.824574e-01 | 0.417 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 2.585010e-01 | 0.588 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.954504e-01 | 0.403 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 2.615952e-01 | 0.582 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.170280e-01 | 0.499 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 4.055209e-01 | 0.392 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 3.594826e-01 | 0.444 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.346148e-01 | 0.630 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 2.346148e-01 | 0.630 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 1.773737e-01 | 0.751 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.779584e-01 | 0.423 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.166968e-01 | 0.664 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 4.715532e-01 | 0.326 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 4.209525e-01 | 0.376 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 2.812620e-01 | 0.551 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 2.137458e-01 | 0.670 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 2.137458e-01 | 0.670 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.108166e-01 | 0.676 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 4.541414e-01 | 0.343 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.108166e-01 | 0.676 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 2.829026e-01 | 0.548 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 2.829026e-01 | 0.548 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 2.413982e-01 | 0.617 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 1.786695e-01 | 0.748 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.729606e-01 | 0.428 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.481718e-01 | 0.605 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 1.856037e-01 | 0.731 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 3.861041e-01 | 0.413 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 4.313501e-01 | 0.365 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 2.667816e-01 | 0.574 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 4.814983e-01 | 0.317 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 4.814983e-01 | 0.317 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.814983e-01 | 0.317 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.814983e-01 | 0.317 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.814983e-01 | 0.317 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 4.814983e-01 | 0.317 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.814983e-01 | 0.317 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.814983e-01 | 0.317 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.814983e-01 | 0.317 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.814983e-01 | 0.317 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.863194e-01 | 0.313 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 4.863194e-01 | 0.313 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 4.863194e-01 | 0.313 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 4.863194e-01 | 0.313 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 4.883845e-01 | 0.311 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.883845e-01 | 0.311 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 4.883845e-01 | 0.311 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 4.883845e-01 | 0.311 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 4.883845e-01 | 0.311 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 4.883845e-01 | 0.311 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 4.883845e-01 | 0.311 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 4.883845e-01 | 0.311 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 4.883845e-01 | 0.311 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.927118e-01 | 0.307 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.965422e-01 | 0.304 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.012801e-01 | 0.300 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.012801e-01 | 0.300 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.075810e-01 | 0.294 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 5.091518e-01 | 0.293 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 5.091518e-01 | 0.293 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 5.091518e-01 | 0.293 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 5.091518e-01 | 0.293 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 5.091518e-01 | 0.293 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 5.091518e-01 | 0.293 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 5.091518e-01 | 0.293 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 5.091518e-01 | 0.293 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 5.091518e-01 | 0.293 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 5.096677e-01 | 0.293 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 5.107657e-01 | 0.292 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 5.107657e-01 | 0.292 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 5.117122e-01 | 0.291 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 5.119311e-01 | 0.291 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.126301e-01 | 0.290 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 5.135136e-01 | 0.289 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 5.143589e-01 | 0.289 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 5.183500e-01 | 0.285 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.183877e-01 | 0.285 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 5.206381e-01 | 0.283 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 5.206381e-01 | 0.283 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 5.228788e-01 | 0.282 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.231809e-01 | 0.281 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 5.276141e-01 | 0.278 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 5.284868e-01 | 0.277 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 5.284868e-01 | 0.277 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 5.307029e-01 | 0.275 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.307407e-01 | 0.275 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.347232e-01 | 0.272 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.359929e-01 | 0.271 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.359929e-01 | 0.271 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 5.400291e-01 | 0.268 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.401064e-01 | 0.268 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.415926e-01 | 0.266 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.415926e-01 | 0.266 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 5.447180e-01 | 0.264 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 5.453370e-01 | 0.263 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.453370e-01 | 0.263 | 0 | 0 |
| Alanine metabolism | R-HSA-8964540 | 5.453370e-01 | 0.263 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.453370e-01 | 0.263 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.453370e-01 | 0.263 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 5.486976e-01 | 0.261 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 5.487108e-01 | 0.261 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 5.487108e-01 | 0.261 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.487108e-01 | 0.261 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 5.487108e-01 | 0.261 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 5.487108e-01 | 0.261 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.487108e-01 | 0.261 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 5.487108e-01 | 0.261 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 5.487108e-01 | 0.261 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 5.487108e-01 | 0.261 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.489613e-01 | 0.260 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.509755e-01 | 0.259 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 5.517501e-01 | 0.258 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.517501e-01 | 0.258 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.517501e-01 | 0.258 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.517501e-01 | 0.258 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 5.517501e-01 | 0.258 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 5.549461e-01 | 0.256 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 5.549461e-01 | 0.256 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 5.549461e-01 | 0.256 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 5.559703e-01 | 0.255 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 5.559703e-01 | 0.255 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.565223e-01 | 0.255 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 5.581311e-01 | 0.253 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 5.631315e-01 | 0.249 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.642436e-01 | 0.249 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 5.642436e-01 | 0.249 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 5.642436e-01 | 0.249 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 5.642436e-01 | 0.249 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.661969e-01 | 0.247 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 5.691245e-01 | 0.245 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.719310e-01 | 0.243 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.726516e-01 | 0.242 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.746301e-01 | 0.241 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.805899e-01 | 0.236 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 5.805899e-01 | 0.236 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 5.809369e-01 | 0.236 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.816307e-01 | 0.235 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 5.816307e-01 | 0.235 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 5.816307e-01 | 0.235 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 5.816307e-01 | 0.235 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 5.816307e-01 | 0.235 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.816307e-01 | 0.235 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 5.816307e-01 | 0.235 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 5.816307e-01 | 0.235 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.819713e-01 | 0.235 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.819713e-01 | 0.235 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 5.819713e-01 | 0.235 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 5.819713e-01 | 0.235 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.819713e-01 | 0.235 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.859730e-01 | 0.232 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 5.859730e-01 | 0.232 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.859730e-01 | 0.232 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 5.859730e-01 | 0.232 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.859730e-01 | 0.232 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.859730e-01 | 0.232 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 5.859730e-01 | 0.232 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 5.859730e-01 | 0.232 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 5.859730e-01 | 0.232 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.859730e-01 | 0.232 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.867388e-01 | 0.232 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.867388e-01 | 0.232 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.885506e-01 | 0.230 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.922660e-01 | 0.227 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 5.957554e-01 | 0.225 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 5.978508e-01 | 0.223 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 6.013190e-01 | 0.221 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 6.013190e-01 | 0.221 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 6.013190e-01 | 0.221 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 6.013190e-01 | 0.221 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 6.013190e-01 | 0.221 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 6.013190e-01 | 0.221 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 6.013190e-01 | 0.221 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 6.013190e-01 | 0.221 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 6.013190e-01 | 0.221 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 6.013190e-01 | 0.221 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 6.013190e-01 | 0.221 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.013190e-01 | 0.221 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 6.013190e-01 | 0.221 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 6.013190e-01 | 0.221 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 6.013190e-01 | 0.221 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 6.020917e-01 | 0.220 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 6.021940e-01 | 0.220 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.030960e-01 | 0.220 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.035714e-01 | 0.219 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 6.041748e-01 | 0.219 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.053628e-01 | 0.218 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.091586e-01 | 0.215 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 6.091586e-01 | 0.215 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 6.102153e-01 | 0.215 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.102153e-01 | 0.215 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 6.196050e-01 | 0.208 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.205074e-01 | 0.207 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 6.209041e-01 | 0.207 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.209041e-01 | 0.207 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.209041e-01 | 0.207 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 6.209041e-01 | 0.207 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 6.209041e-01 | 0.207 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 6.209041e-01 | 0.207 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 6.209041e-01 | 0.207 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 6.209041e-01 | 0.207 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 6.209041e-01 | 0.207 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 6.209041e-01 | 0.207 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 6.218744e-01 | 0.206 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.218744e-01 | 0.206 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.218744e-01 | 0.206 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 6.218744e-01 | 0.206 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.245714e-01 | 0.204 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 6.285926e-01 | 0.202 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 6.292221e-01 | 0.201 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 6.292221e-01 | 0.201 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 6.292221e-01 | 0.201 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 6.292221e-01 | 0.201 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 6.318768e-01 | 0.199 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 6.345316e-01 | 0.198 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 6.348678e-01 | 0.197 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 6.353901e-01 | 0.197 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.374607e-01 | 0.196 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 6.409862e-01 | 0.193 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.453332e-01 | 0.190 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.473979e-01 | 0.189 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 6.486045e-01 | 0.188 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.504110e-01 | 0.187 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.504110e-01 | 0.187 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 6.504110e-01 | 0.187 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.504110e-01 | 0.187 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.504110e-01 | 0.187 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.504110e-01 | 0.187 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.504110e-01 | 0.187 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.504110e-01 | 0.187 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.504110e-01 | 0.187 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 6.504110e-01 | 0.187 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 6.504110e-01 | 0.187 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.504110e-01 | 0.187 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.504110e-01 | 0.187 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.504110e-01 | 0.187 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.504110e-01 | 0.187 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.504110e-01 | 0.187 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 6.504110e-01 | 0.187 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.504110e-01 | 0.187 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.504110e-01 | 0.187 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.504110e-01 | 0.187 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.504110e-01 | 0.187 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 6.504110e-01 | 0.187 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.504110e-01 | 0.187 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 6.521359e-01 | 0.186 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.521359e-01 | 0.186 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 6.521359e-01 | 0.186 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.521359e-01 | 0.186 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 6.521359e-01 | 0.186 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 6.521359e-01 | 0.186 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 6.521359e-01 | 0.186 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 6.535132e-01 | 0.185 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 6.535132e-01 | 0.185 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 6.535132e-01 | 0.185 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 6.535132e-01 | 0.185 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 6.535132e-01 | 0.185 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 6.535132e-01 | 0.185 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 6.620765e-01 | 0.179 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 6.633430e-01 | 0.178 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 6.633430e-01 | 0.178 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 6.633430e-01 | 0.178 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 6.633430e-01 | 0.178 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 6.633430e-01 | 0.178 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 6.633430e-01 | 0.178 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.653585e-01 | 0.177 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.653585e-01 | 0.177 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.653585e-01 | 0.177 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 6.656788e-01 | 0.177 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 6.726841e-01 | 0.172 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 6.740829e-01 | 0.171 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 6.740829e-01 | 0.171 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 6.740829e-01 | 0.171 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.740829e-01 | 0.171 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.805182e-01 | 0.167 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 6.835899e-01 | 0.165 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 6.838425e-01 | 0.165 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 6.838425e-01 | 0.165 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 6.838425e-01 | 0.165 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 6.838425e-01 | 0.165 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 6.838425e-01 | 0.165 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 6.838425e-01 | 0.165 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.838945e-01 | 0.165 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 6.878547e-01 | 0.163 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.878547e-01 | 0.163 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.878547e-01 | 0.163 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.878547e-01 | 0.163 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 6.878547e-01 | 0.163 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 6.885373e-01 | 0.162 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.886624e-01 | 0.162 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.934604e-01 | 0.159 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.934604e-01 | 0.159 | 0 | 0 |
| Highly sodium permeable postsynaptic acetylcholine nicotinic receptors | R-HSA-629587 | 6.934604e-01 | 0.159 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.934604e-01 | 0.159 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.934604e-01 | 0.159 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.934604e-01 | 0.159 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.934604e-01 | 0.159 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.934604e-01 | 0.159 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.934604e-01 | 0.159 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 6.934604e-01 | 0.159 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.934604e-01 | 0.159 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 6.934604e-01 | 0.159 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.946294e-01 | 0.158 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 6.950506e-01 | 0.158 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 6.950506e-01 | 0.158 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.951649e-01 | 0.158 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 6.989238e-01 | 0.156 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 6.994677e-01 | 0.155 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.110020e-01 | 0.148 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.110020e-01 | 0.148 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.112667e-01 | 0.148 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 7.119590e-01 | 0.148 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 7.119590e-01 | 0.148 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 7.119590e-01 | 0.148 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.119590e-01 | 0.148 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 7.119590e-01 | 0.148 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 7.119590e-01 | 0.148 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 7.119590e-01 | 0.148 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 7.119590e-01 | 0.148 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.119590e-01 | 0.148 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 7.139503e-01 | 0.146 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 7.150350e-01 | 0.146 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.150350e-01 | 0.146 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 7.195031e-01 | 0.143 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 7.208760e-01 | 0.142 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.274129e-01 | 0.138 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.312108e-01 | 0.136 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 7.312108e-01 | 0.136 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 7.312108e-01 | 0.136 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 7.312108e-01 | 0.136 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.312108e-01 | 0.136 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 7.312108e-01 | 0.136 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 7.312108e-01 | 0.136 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 7.312108e-01 | 0.136 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.312108e-01 | 0.136 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.312108e-01 | 0.136 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 7.312108e-01 | 0.136 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.312108e-01 | 0.136 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 7.312108e-01 | 0.136 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 7.312108e-01 | 0.136 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 7.312108e-01 | 0.136 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.312108e-01 | 0.136 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 7.312108e-01 | 0.136 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.328028e-01 | 0.135 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.349996e-01 | 0.134 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.378427e-01 | 0.132 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.379475e-01 | 0.132 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.379475e-01 | 0.132 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 7.379475e-01 | 0.132 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 7.379475e-01 | 0.132 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.379475e-01 | 0.132 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 7.379475e-01 | 0.132 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.399428e-01 | 0.131 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.490878e-01 | 0.125 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.490878e-01 | 0.125 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.490878e-01 | 0.125 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.511331e-01 | 0.124 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 7.520724e-01 | 0.124 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 7.532849e-01 | 0.123 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 7.532849e-01 | 0.123 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.540419e-01 | 0.123 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.540419e-01 | 0.123 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 7.542996e-01 | 0.122 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.616838e-01 | 0.118 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 7.619057e-01 | 0.118 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.619057e-01 | 0.118 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 7.619057e-01 | 0.118 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 7.619057e-01 | 0.118 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 7.619057e-01 | 0.118 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 7.619057e-01 | 0.118 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 7.619057e-01 | 0.118 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.624696e-01 | 0.118 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.643142e-01 | 0.117 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.643142e-01 | 0.117 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 7.643142e-01 | 0.117 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.643142e-01 | 0.117 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.643142e-01 | 0.117 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.643142e-01 | 0.117 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 7.643142e-01 | 0.117 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 7.643142e-01 | 0.117 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.643142e-01 | 0.117 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.643142e-01 | 0.117 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 7.643142e-01 | 0.117 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.643142e-01 | 0.117 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 7.666499e-01 | 0.115 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 7.691496e-01 | 0.114 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.691496e-01 | 0.114 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 7.694807e-01 | 0.114 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 7.694807e-01 | 0.114 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.716956e-01 | 0.113 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 7.724835e-01 | 0.112 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 7.724835e-01 | 0.112 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 7.724835e-01 | 0.112 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.724835e-01 | 0.112 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 7.724835e-01 | 0.112 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 7.724835e-01 | 0.112 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.724835e-01 | 0.112 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.749486e-01 | 0.111 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.795106e-01 | 0.108 | 0 | 0 |
| Protein folding | R-HSA-391251 | 7.816773e-01 | 0.107 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.816773e-01 | 0.107 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.829680e-01 | 0.106 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.839395e-01 | 0.106 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 7.839395e-01 | 0.106 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.839395e-01 | 0.106 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.839395e-01 | 0.106 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 7.841697e-01 | 0.106 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 7.841697e-01 | 0.106 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.852903e-01 | 0.105 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 7.852903e-01 | 0.105 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 7.852903e-01 | 0.105 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 7.852903e-01 | 0.105 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 7.869734e-01 | 0.104 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 7.874631e-01 | 0.104 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 7.890879e-01 | 0.103 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 7.904403e-01 | 0.102 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 7.904403e-01 | 0.102 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 7.904403e-01 | 0.102 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.933423e-01 | 0.101 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.933423e-01 | 0.101 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.933423e-01 | 0.101 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.933423e-01 | 0.101 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.933423e-01 | 0.101 | 0 | 0 |
| Degradation of GABA | R-HSA-916853 | 7.933423e-01 | 0.101 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.933423e-01 | 0.101 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.933423e-01 | 0.101 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.933423e-01 | 0.101 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.933423e-01 | 0.101 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.933423e-01 | 0.101 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.939439e-01 | 0.100 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 7.980869e-01 | 0.098 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 8.016734e-01 | 0.096 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 8.041593e-01 | 0.095 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 8.041593e-01 | 0.095 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 8.041593e-01 | 0.095 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 8.041593e-01 | 0.095 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 8.041593e-01 | 0.095 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.072016e-01 | 0.093 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.109115e-01 | 0.091 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 8.109140e-01 | 0.091 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 8.124243e-01 | 0.090 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 8.124243e-01 | 0.090 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.145711e-01 | 0.089 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.148586e-01 | 0.089 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.148586e-01 | 0.089 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 8.187967e-01 | 0.087 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.187967e-01 | 0.087 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.187967e-01 | 0.087 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.187967e-01 | 0.087 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.187967e-01 | 0.087 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.187967e-01 | 0.087 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.187967e-01 | 0.087 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 8.187967e-01 | 0.087 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 8.187967e-01 | 0.087 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 8.187967e-01 | 0.087 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.187967e-01 | 0.087 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 8.187967e-01 | 0.087 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 8.218622e-01 | 0.085 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 8.226777e-01 | 0.085 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 8.226777e-01 | 0.085 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.238849e-01 | 0.084 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.238849e-01 | 0.084 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 8.260992e-01 | 0.083 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 8.283418e-01 | 0.082 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.283418e-01 | 0.082 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 8.283418e-01 | 0.082 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.287480e-01 | 0.082 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 8.323103e-01 | 0.080 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 8.326267e-01 | 0.080 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 8.331681e-01 | 0.079 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.373396e-01 | 0.077 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 8.396070e-01 | 0.076 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 8.396070e-01 | 0.076 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 8.396070e-01 | 0.076 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 8.411171e-01 | 0.075 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.411171e-01 | 0.075 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.411171e-01 | 0.075 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 8.411171e-01 | 0.075 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.411171e-01 | 0.075 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.411171e-01 | 0.075 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.411171e-01 | 0.075 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 8.411171e-01 | 0.075 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 8.411171e-01 | 0.075 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 8.495768e-01 | 0.071 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 8.505922e-01 | 0.070 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.508222e-01 | 0.070 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 8.508222e-01 | 0.070 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.508222e-01 | 0.070 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.508222e-01 | 0.070 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.528613e-01 | 0.069 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 8.550575e-01 | 0.068 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 8.550575e-01 | 0.068 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 8.550575e-01 | 0.068 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 8.550575e-01 | 0.068 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 8.550575e-01 | 0.068 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 8.574692e-01 | 0.067 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.606892e-01 | 0.065 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.606892e-01 | 0.065 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.606892e-01 | 0.065 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.606892e-01 | 0.065 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 8.606892e-01 | 0.065 | 0 | 0 |
| Presynaptic nicotinic acetylcholine receptors | R-HSA-622323 | 8.606892e-01 | 0.065 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 8.606892e-01 | 0.065 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 8.606892e-01 | 0.065 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.633197e-01 | 0.064 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 8.633197e-01 | 0.064 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.639638e-01 | 0.064 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 8.684561e-01 | 0.061 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 8.691366e-01 | 0.061 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.712508e-01 | 0.060 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 8.721322e-01 | 0.059 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.726397e-01 | 0.059 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 8.743402e-01 | 0.058 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 8.755464e-01 | 0.058 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.778513e-01 | 0.057 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.778513e-01 | 0.057 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.778513e-01 | 0.057 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.778513e-01 | 0.057 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.778513e-01 | 0.057 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.778513e-01 | 0.057 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.778513e-01 | 0.057 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.778513e-01 | 0.057 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.778513e-01 | 0.057 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.778513e-01 | 0.057 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 8.819478e-01 | 0.055 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 8.819478e-01 | 0.055 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 8.819478e-01 | 0.055 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 8.819478e-01 | 0.055 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 8.819478e-01 | 0.055 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 8.819478e-01 | 0.055 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.819478e-01 | 0.055 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 8.819478e-01 | 0.055 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 8.829517e-01 | 0.054 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.832099e-01 | 0.054 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.849286e-01 | 0.053 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.851650e-01 | 0.053 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.855767e-01 | 0.053 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 8.873767e-01 | 0.052 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.899881e-01 | 0.051 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.918915e-01 | 0.050 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.929001e-01 | 0.049 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 8.929001e-01 | 0.049 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 8.929001e-01 | 0.049 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.929001e-01 | 0.049 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 8.929001e-01 | 0.049 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 8.929001e-01 | 0.049 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.929001e-01 | 0.049 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.929001e-01 | 0.049 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.929001e-01 | 0.049 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.929001e-01 | 0.049 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 8.930528e-01 | 0.049 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.937592e-01 | 0.049 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.937592e-01 | 0.049 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 8.966679e-01 | 0.047 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 8.991498e-01 | 0.046 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.041556e-01 | 0.044 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.041556e-01 | 0.044 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.041556e-01 | 0.044 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.045377e-01 | 0.044 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.045377e-01 | 0.044 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.045377e-01 | 0.044 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 9.060956e-01 | 0.043 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 9.060956e-01 | 0.043 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 9.060956e-01 | 0.043 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 9.060956e-01 | 0.043 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.060956e-01 | 0.043 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 9.060956e-01 | 0.043 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.060956e-01 | 0.043 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 9.060956e-01 | 0.043 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.089020e-01 | 0.041 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.090072e-01 | 0.041 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.092734e-01 | 0.041 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 9.093399e-01 | 0.041 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.129104e-01 | 0.040 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 9.137342e-01 | 0.039 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 9.137342e-01 | 0.039 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.137342e-01 | 0.039 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.141531e-01 | 0.039 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.161114e-01 | 0.038 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.165330e-01 | 0.038 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.176660e-01 | 0.037 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.176660e-01 | 0.037 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 9.176660e-01 | 0.037 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 9.176660e-01 | 0.037 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 9.176660e-01 | 0.037 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.176660e-01 | 0.037 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.176660e-01 | 0.037 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 9.176660e-01 | 0.037 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.176660e-01 | 0.037 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.177234e-01 | 0.037 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.177844e-01 | 0.037 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 9.206095e-01 | 0.036 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.206095e-01 | 0.036 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 9.206095e-01 | 0.036 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.206095e-01 | 0.036 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 9.217733e-01 | 0.035 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.224082e-01 | 0.035 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.224082e-01 | 0.035 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.224082e-01 | 0.035 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.224082e-01 | 0.035 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.224082e-01 | 0.035 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.232686e-01 | 0.035 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 9.238387e-01 | 0.034 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.274413e-01 | 0.033 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 9.278113e-01 | 0.033 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.278113e-01 | 0.033 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.278113e-01 | 0.033 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.278113e-01 | 0.033 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 9.278113e-01 | 0.033 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.278113e-01 | 0.033 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.295115e-01 | 0.032 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.295115e-01 | 0.032 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.326786e-01 | 0.030 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.341702e-01 | 0.030 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.361522e-01 | 0.029 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 9.367071e-01 | 0.028 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 9.367071e-01 | 0.028 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 9.367071e-01 | 0.028 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.367071e-01 | 0.028 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 9.367071e-01 | 0.028 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.367071e-01 | 0.028 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.367071e-01 | 0.028 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 9.367071e-01 | 0.028 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.373469e-01 | 0.028 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.377985e-01 | 0.028 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.382751e-01 | 0.028 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 9.406385e-01 | 0.027 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.427805e-01 | 0.026 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.437506e-01 | 0.025 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.437506e-01 | 0.025 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.445071e-01 | 0.025 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.445071e-01 | 0.025 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.445071e-01 | 0.025 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.445071e-01 | 0.025 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 9.445071e-01 | 0.025 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.445071e-01 | 0.025 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.445071e-01 | 0.025 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.455644e-01 | 0.024 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.455644e-01 | 0.024 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.455644e-01 | 0.024 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 9.462804e-01 | 0.024 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.465707e-01 | 0.024 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.474652e-01 | 0.023 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.475081e-01 | 0.023 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.495280e-01 | 0.022 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.501413e-01 | 0.022 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.501413e-01 | 0.022 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.501413e-01 | 0.022 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.505472e-01 | 0.022 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.505472e-01 | 0.022 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.513462e-01 | 0.022 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 9.513462e-01 | 0.022 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.513462e-01 | 0.022 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.515789e-01 | 0.022 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.515789e-01 | 0.022 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.519306e-01 | 0.021 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.533818e-01 | 0.021 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 9.547361e-01 | 0.020 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.547361e-01 | 0.020 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.547361e-01 | 0.020 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.547361e-01 | 0.020 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.547361e-01 | 0.020 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.551017e-01 | 0.020 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.551017e-01 | 0.020 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.551017e-01 | 0.020 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.551017e-01 | 0.020 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.560316e-01 | 0.020 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.566399e-01 | 0.019 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.573428e-01 | 0.019 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.573428e-01 | 0.019 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.573428e-01 | 0.019 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.573428e-01 | 0.019 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.573428e-01 | 0.019 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.573428e-01 | 0.019 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.582278e-01 | 0.019 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.582278e-01 | 0.019 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 9.582278e-01 | 0.019 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.610793e-01 | 0.017 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 9.626006e-01 | 0.017 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.626006e-01 | 0.017 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.626006e-01 | 0.017 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 9.626006e-01 | 0.017 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.626006e-01 | 0.017 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.626006e-01 | 0.017 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.630568e-01 | 0.016 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.636506e-01 | 0.016 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.649380e-01 | 0.016 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 9.650859e-01 | 0.015 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.653669e-01 | 0.015 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.656330e-01 | 0.015 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.663304e-01 | 0.015 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.665175e-01 | 0.015 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.665175e-01 | 0.015 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.672106e-01 | 0.014 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 9.672106e-01 | 0.014 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.672106e-01 | 0.014 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.674493e-01 | 0.014 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 9.681077e-01 | 0.014 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.689123e-01 | 0.014 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.693872e-01 | 0.014 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.696706e-01 | 0.013 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.696706e-01 | 0.013 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.706745e-01 | 0.013 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.708641e-01 | 0.013 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.708641e-01 | 0.013 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.708641e-01 | 0.013 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.708641e-01 | 0.013 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.708641e-01 | 0.013 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.708641e-01 | 0.013 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.708840e-01 | 0.013 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 9.712527e-01 | 0.013 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.712527e-01 | 0.013 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.712527e-01 | 0.013 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 9.716557e-01 | 0.012 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.716710e-01 | 0.012 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.725412e-01 | 0.012 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.734328e-01 | 0.012 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.734328e-01 | 0.012 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.735066e-01 | 0.012 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.739319e-01 | 0.011 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.747966e-01 | 0.011 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 9.747966e-01 | 0.011 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.747966e-01 | 0.011 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 9.747966e-01 | 0.011 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.747966e-01 | 0.011 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.752968e-01 | 0.011 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.766863e-01 | 0.010 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 9.769372e-01 | 0.010 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.779038e-01 | 0.010 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.779038e-01 | 0.010 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.779038e-01 | 0.010 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.779038e-01 | 0.010 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.779038e-01 | 0.010 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.779038e-01 | 0.010 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.779151e-01 | 0.010 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.779151e-01 | 0.010 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.791581e-01 | 0.009 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.791581e-01 | 0.009 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.791581e-01 | 0.009 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.791581e-01 | 0.009 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.791581e-01 | 0.009 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.796845e-01 | 0.009 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.798793e-01 | 0.009 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.806282e-01 | 0.008 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.806282e-01 | 0.008 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.806282e-01 | 0.008 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.806282e-01 | 0.008 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.806282e-01 | 0.008 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.813749e-01 | 0.008 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.813749e-01 | 0.008 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.816777e-01 | 0.008 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.820149e-01 | 0.008 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.822692e-01 | 0.008 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.830167e-01 | 0.007 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.830167e-01 | 0.007 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.833620e-01 | 0.007 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.833620e-01 | 0.007 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.833620e-01 | 0.007 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.833620e-01 | 0.007 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.840510e-01 | 0.007 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.850327e-01 | 0.007 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.851109e-01 | 0.007 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.851109e-01 | 0.007 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.851109e-01 | 0.007 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.851425e-01 | 0.007 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.852008e-01 | 0.006 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.857465e-01 | 0.006 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.864560e-01 | 0.006 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.864937e-01 | 0.006 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.867370e-01 | 0.006 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.869147e-01 | 0.006 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.869469e-01 | 0.006 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.869469e-01 | 0.006 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.869469e-01 | 0.006 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.869469e-01 | 0.006 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.869469e-01 | 0.006 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.869469e-01 | 0.006 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.869469e-01 | 0.006 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.869469e-01 | 0.006 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.874597e-01 | 0.005 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.878018e-01 | 0.005 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.878172e-01 | 0.005 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.885567e-01 | 0.005 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 9.885567e-01 | 0.005 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.886065e-01 | 0.005 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.886870e-01 | 0.005 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.894413e-01 | 0.005 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.894413e-01 | 0.005 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.899680e-01 | 0.004 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.899680e-01 | 0.004 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.899680e-01 | 0.004 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.900998e-01 | 0.004 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.905835e-01 | 0.004 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 9.905835e-01 | 0.004 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.905835e-01 | 0.004 | 0 | 0 |
| Mucopolysaccharidoses | R-HSA-2206281 | 9.912053e-01 | 0.004 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.916047e-01 | 0.004 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 9.919334e-01 | 0.004 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 9.919672e-01 | 0.004 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.922686e-01 | 0.003 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.922901e-01 | 0.003 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.925172e-01 | 0.003 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.925172e-01 | 0.003 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.925172e-01 | 0.003 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.932411e-01 | 0.003 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.932411e-01 | 0.003 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.933325e-01 | 0.003 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.934918e-01 | 0.003 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.940309e-01 | 0.003 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.940605e-01 | 0.003 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.941418e-01 | 0.003 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.941450e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.947105e-01 | 0.002 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.948058e-01 | 0.002 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.948058e-01 | 0.002 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.948058e-01 | 0.002 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.952905e-01 | 0.002 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.954466e-01 | 0.002 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.958079e-01 | 0.002 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.958636e-01 | 0.002 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.960084e-01 | 0.002 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.960084e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.960084e-01 | 0.002 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.960718e-01 | 0.002 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.961345e-01 | 0.002 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.962694e-01 | 0.002 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 9.965009e-01 | 0.002 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.966809e-01 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.969171e-01 | 0.001 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.969327e-01 | 0.001 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.969327e-01 | 0.001 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.969327e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.971354e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.973112e-01 | 0.001 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.973112e-01 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.973315e-01 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.973315e-01 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.974105e-01 | 0.001 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.976430e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.976430e-01 | 0.001 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.976902e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.977345e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.979197e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.979339e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.980017e-01 | 0.001 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.981889e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.982082e-01 | 0.001 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.982561e-01 | 0.001 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.984125e-01 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.984522e-01 | 0.001 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.984928e-01 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.985441e-01 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.985606e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.986168e-01 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.987068e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.987103e-01 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.987802e-01 | 0.001 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.989308e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.989308e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.989773e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.989803e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.990628e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.991148e-01 | 0.000 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.991785e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.991965e-01 | 0.000 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.992799e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.992799e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.993564e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.993812e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.994387e-01 | 0.000 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 9.994468e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.995652e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.995750e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.996528e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.996528e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.996922e-01 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.997120e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.997492e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.997802e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.997802e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.997857e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.998073e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.998146e-01 | 0.000 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.998510e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.998520e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.998520e-01 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.998653e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.998703e-01 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.998703e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.998863e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.998965e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.999127e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999134e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.999235e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999282e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.999296e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.999329e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999437e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999485e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999549e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999560e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.999605e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999610e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999630e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.999653e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999693e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999695e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.999696e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999767e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999813e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999815e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999836e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999894e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999921e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999950e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999963e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999967e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999971e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999974e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999982e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999984e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999988e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999992e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999994e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999996e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999996e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999997e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999997e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999999e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.110223e-16 | 15.955 | 0 | 0 |
| M Phase | R-HSA-68886 | 4.540812e-14 | 13.343 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 8.761070e-11 | 10.057 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.384606e-10 | 9.859 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 6.772646e-10 | 9.169 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.299937e-09 | 8.481 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.759846e-09 | 8.240 | 1 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 7.745778e-09 | 8.111 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.407053e-08 | 7.619 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.287556e-08 | 7.368 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.809325e-08 | 7.318 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 6.219318e-08 | 7.206 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 6.784971e-08 | 7.168 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.208609e-07 | 6.918 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.128571e-07 | 6.672 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.084007e-07 | 6.681 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 6.921340e-07 | 6.160 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 7.289474e-07 | 6.137 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.205345e-06 | 5.919 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.197744e-06 | 5.922 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.349639e-06 | 5.870 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.520583e-06 | 5.818 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.875915e-06 | 5.727 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.875915e-06 | 5.727 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.918492e-06 | 5.717 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.794572e-06 | 5.746 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.252235e-06 | 5.647 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 3.191451e-06 | 5.496 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.513934e-06 | 5.454 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.076055e-06 | 5.390 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 5.270644e-06 | 5.278 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 5.270644e-06 | 5.278 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 5.077663e-06 | 5.294 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 5.730312e-06 | 5.242 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 6.113771e-06 | 5.214 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 6.580208e-06 | 5.182 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 6.580208e-06 | 5.182 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 6.592714e-06 | 5.181 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 8.444145e-06 | 5.073 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 9.475548e-06 | 5.023 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.906236e-06 | 5.004 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.396627e-05 | 4.855 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.427580e-05 | 4.845 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.579808e-05 | 4.801 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.738648e-05 | 4.760 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.791357e-05 | 4.747 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.101576e-05 | 4.677 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.187892e-05 | 4.660 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.584402e-05 | 4.588 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.599798e-05 | 4.585 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 2.883313e-05 | 4.540 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.764231e-05 | 4.558 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.828055e-05 | 4.549 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 2.807685e-05 | 4.552 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.706622e-05 | 4.568 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.931395e-05 | 4.533 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 3.268602e-05 | 4.486 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 3.357468e-05 | 4.474 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.455087e-05 | 4.462 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 3.618496e-05 | 4.441 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.700605e-05 | 4.432 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.700605e-05 | 4.432 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 4.351210e-05 | 4.361 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 4.728018e-05 | 4.325 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 4.785462e-05 | 4.320 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 5.461852e-05 | 4.263 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 5.591337e-05 | 4.252 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 6.485260e-05 | 4.188 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 6.414748e-05 | 4.193 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 6.414748e-05 | 4.193 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.485260e-05 | 4.188 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 6.577299e-05 | 4.182 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 7.876396e-05 | 4.104 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.540203e-05 | 4.123 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 8.178039e-05 | 4.087 | 1 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 9.451481e-05 | 4.025 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 9.165728e-05 | 4.038 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 9.165728e-05 | 4.038 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 9.985758e-05 | 4.001 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.054584e-04 | 3.977 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.089135e-04 | 3.963 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.193804e-04 | 3.923 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.241465e-04 | 3.906 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.289986e-04 | 3.889 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.343250e-04 | 3.872 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.402891e-04 | 3.853 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.452430e-04 | 3.838 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.628735e-04 | 3.788 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.628735e-04 | 3.788 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.607046e-04 | 3.794 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.548488e-04 | 3.810 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.671620e-04 | 3.777 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.732580e-04 | 3.761 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.908232e-04 | 3.719 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 2.056176e-04 | 3.687 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.195348e-04 | 3.658 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.213150e-04 | 3.655 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 2.448359e-04 | 3.611 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.537293e-04 | 3.596 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.556538e-04 | 3.592 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.718868e-04 | 3.566 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.561317e-04 | 3.592 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.748395e-04 | 3.561 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.782082e-04 | 3.556 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 3.038433e-04 | 3.517 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.943699e-04 | 3.531 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.905111e-04 | 3.537 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.202749e-04 | 3.494 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.513424e-04 | 3.454 | 1 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.543983e-04 | 3.451 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.545391e-04 | 3.450 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 4.538889e-04 | 3.343 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.558358e-04 | 3.341 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 5.200974e-04 | 3.284 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 5.224763e-04 | 3.282 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 5.496987e-04 | 3.260 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 5.496987e-04 | 3.260 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 5.680522e-04 | 3.246 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.523607e-04 | 3.258 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.615538e-04 | 3.251 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 5.942884e-04 | 3.226 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 5.933831e-04 | 3.227 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.615538e-04 | 3.251 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.074028e-04 | 3.217 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 6.093184e-04 | 3.215 | 1 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.113986e-04 | 3.214 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.434626e-04 | 3.191 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 6.453875e-04 | 3.190 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 6.576617e-04 | 3.182 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 6.843665e-04 | 3.165 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 6.985200e-04 | 3.156 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 7.182572e-04 | 3.144 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 6.811803e-04 | 3.167 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 7.244497e-04 | 3.140 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 7.295687e-04 | 3.137 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 7.330905e-04 | 3.135 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 7.833160e-04 | 3.106 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 7.952441e-04 | 3.099 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 8.076884e-04 | 3.093 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.740443e-04 | 3.058 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 8.801031e-04 | 3.055 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.202500e-04 | 3.036 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.309986e-04 | 3.031 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 9.987010e-04 | 3.001 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.098319e-03 | 2.959 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.026120e-03 | 2.989 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.185457e-03 | 2.926 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.225175e-03 | 2.912 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.273896e-03 | 2.895 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.304941e-03 | 2.884 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.422077e-03 | 2.847 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.494438e-03 | 2.826 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.494438e-03 | 2.826 | 1 | 1 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.510671e-03 | 2.821 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.516264e-03 | 2.819 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.560334e-03 | 2.807 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.665365e-03 | 2.778 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.708625e-03 | 2.767 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.948557e-03 | 2.710 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.964711e-03 | 2.707 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 2.069488e-03 | 2.684 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.302061e-03 | 2.638 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 2.308048e-03 | 2.637 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.434183e-03 | 2.614 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.604729e-03 | 2.584 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.623238e-03 | 2.581 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.706873e-03 | 2.568 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.954549e-03 | 2.530 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.910623e-03 | 2.536 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 3.149474e-03 | 2.502 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 3.029531e-03 | 2.519 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.074432e-03 | 2.512 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 3.159833e-03 | 2.500 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 3.159833e-03 | 2.500 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.502827e-03 | 2.456 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 3.555177e-03 | 2.449 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 3.573504e-03 | 2.447 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 3.573504e-03 | 2.447 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.610504e-03 | 2.442 | 0 | 0 |
| Depurination | R-HSA-73927 | 3.665656e-03 | 2.436 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 3.794208e-03 | 2.421 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 3.794208e-03 | 2.421 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.873033e-03 | 2.412 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 4.031386e-03 | 2.395 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.225773e-03 | 2.374 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.225773e-03 | 2.374 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 4.320129e-03 | 2.365 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 4.604463e-03 | 2.337 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 5.040769e-03 | 2.298 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 5.040769e-03 | 2.298 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 5.121961e-03 | 2.291 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 4.649244e-03 | 2.333 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 5.441726e-03 | 2.264 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 5.584789e-03 | 2.253 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 5.851425e-03 | 2.233 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 5.851425e-03 | 2.233 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.042056e-03 | 2.219 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 6.491963e-03 | 2.188 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 6.740470e-03 | 2.171 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.778388e-03 | 2.169 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 6.792284e-03 | 2.168 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 6.792284e-03 | 2.168 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.911905e-03 | 2.160 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 6.944734e-03 | 2.158 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 6.946157e-03 | 2.158 | 0 | 0 |
| S Phase | R-HSA-69242 | 7.199352e-03 | 2.143 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 7.774095e-03 | 2.109 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 7.764471e-03 | 2.110 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 7.764471e-03 | 2.110 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 8.272103e-03 | 2.082 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 7.764471e-03 | 2.110 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 7.266004e-03 | 2.139 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 7.332297e-03 | 2.135 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 8.379004e-03 | 2.077 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 9.638633e-03 | 2.016 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 9.638633e-03 | 2.016 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 9.653967e-03 | 2.015 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.772082e-03 | 2.010 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 9.772082e-03 | 2.010 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 9.772082e-03 | 2.010 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 9.864850e-03 | 2.006 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 9.910303e-03 | 2.004 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.025145e-02 | 1.989 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.088215e-02 | 1.963 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.128950e-02 | 1.947 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.149867e-02 | 1.939 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.180122e-02 | 1.928 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.192874e-02 | 1.923 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.229316e-02 | 1.910 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.231562e-02 | 1.910 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.305393e-02 | 1.884 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.321292e-02 | 1.879 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.322054e-02 | 1.879 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.329066e-02 | 1.876 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.379980e-02 | 1.860 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.593771e-02 | 1.798 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.492849e-02 | 1.826 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.649132e-02 | 1.783 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.649132e-02 | 1.783 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.649132e-02 | 1.783 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.599189e-02 | 1.796 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 1.515886e-02 | 1.819 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 1.515886e-02 | 1.819 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 1.593771e-02 | 1.798 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.646152e-02 | 1.784 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.656732e-02 | 1.781 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.657920e-02 | 1.780 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.679679e-02 | 1.775 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.679993e-02 | 1.775 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.679993e-02 | 1.775 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.760952e-02 | 1.754 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.798328e-02 | 1.745 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.847016e-02 | 1.734 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.847016e-02 | 1.734 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.894592e-02 | 1.722 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.942177e-02 | 1.712 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.942177e-02 | 1.712 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.942177e-02 | 1.712 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.942177e-02 | 1.712 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.942177e-02 | 1.712 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 1.946114e-02 | 1.711 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.095748e-02 | 1.679 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 2.095748e-02 | 1.679 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 2.106982e-02 | 1.676 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.171331e-02 | 1.663 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.202744e-02 | 1.657 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.225829e-02 | 1.653 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 2.225829e-02 | 1.653 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 2.233893e-02 | 1.651 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.233893e-02 | 1.651 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 2.659785e-02 | 1.575 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 2.263904e-02 | 1.645 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.282652e-02 | 1.642 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 2.282652e-02 | 1.642 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.282652e-02 | 1.642 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.655211e-02 | 1.576 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.318150e-02 | 1.635 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.506699e-02 | 1.601 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.697751e-02 | 1.569 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.279503e-02 | 1.642 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.345974e-02 | 1.630 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.263904e-02 | 1.645 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.506699e-02 | 1.601 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.506699e-02 | 1.601 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 2.341941e-02 | 1.630 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 2.659785e-02 | 1.575 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.613905e-02 | 1.583 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.574084e-02 | 1.589 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 2.805421e-02 | 1.552 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 2.805421e-02 | 1.552 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.812991e-02 | 1.551 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.858288e-02 | 1.544 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 2.877232e-02 | 1.541 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.877232e-02 | 1.541 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.898117e-02 | 1.538 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.995402e-02 | 1.524 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.995402e-02 | 1.524 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 3.003144e-02 | 1.522 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.010430e-02 | 1.521 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 3.036698e-02 | 1.518 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 3.067986e-02 | 1.513 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.125420e-02 | 1.505 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.125420e-02 | 1.505 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.144554e-02 | 1.502 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.144554e-02 | 1.502 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.144554e-02 | 1.502 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.144554e-02 | 1.502 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.243879e-02 | 1.489 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.250899e-02 | 1.488 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.370790e-02 | 1.472 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.434154e-02 | 1.464 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.434154e-02 | 1.464 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.434154e-02 | 1.464 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.504163e-02 | 1.455 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 3.504163e-02 | 1.455 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.514917e-02 | 1.454 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 3.913421e-02 | 1.407 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 3.913421e-02 | 1.407 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.913421e-02 | 1.407 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.993925e-02 | 1.399 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.609254e-02 | 1.443 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.609254e-02 | 1.443 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.745429e-02 | 1.426 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.745429e-02 | 1.426 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.438845e-02 | 1.353 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.438845e-02 | 1.353 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 4.215103e-02 | 1.375 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.855316e-02 | 1.414 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 3.908348e-02 | 1.408 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.322264e-02 | 1.364 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 4.310765e-02 | 1.365 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 4.438845e-02 | 1.353 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 4.079305e-02 | 1.389 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 4.017987e-02 | 1.396 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.863026e-02 | 1.413 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 3.745429e-02 | 1.426 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.215103e-02 | 1.375 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.215103e-02 | 1.375 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.206329e-02 | 1.376 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.418942e-02 | 1.355 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.271271e-02 | 1.369 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 4.308450e-02 | 1.366 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.993925e-02 | 1.399 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 4.017987e-02 | 1.396 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 3.855316e-02 | 1.414 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.308450e-02 | 1.366 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.017987e-02 | 1.396 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 4.655168e-02 | 1.332 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.735068e-02 | 1.325 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.735068e-02 | 1.325 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.740891e-02 | 1.324 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 4.914478e-02 | 1.309 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 4.925774e-02 | 1.308 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 4.925774e-02 | 1.308 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 4.925774e-02 | 1.308 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.925774e-02 | 1.308 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 4.948403e-02 | 1.306 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 5.076808e-02 | 1.294 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 5.076808e-02 | 1.294 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 5.076808e-02 | 1.294 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 5.076808e-02 | 1.294 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 5.156443e-02 | 1.288 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.190339e-02 | 1.285 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.207369e-02 | 1.283 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 5.207369e-02 | 1.283 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 5.207369e-02 | 1.283 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 5.207369e-02 | 1.283 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 5.207369e-02 | 1.283 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 5.207369e-02 | 1.283 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 5.328341e-02 | 1.273 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 5.328868e-02 | 1.273 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.328868e-02 | 1.273 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.328868e-02 | 1.273 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.341467e-02 | 1.272 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.373315e-02 | 1.270 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.415071e-02 | 1.266 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.415071e-02 | 1.266 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.415071e-02 | 1.266 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 5.552019e-02 | 1.256 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 5.760581e-02 | 1.240 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.782565e-02 | 1.238 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 5.892074e-02 | 1.230 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 5.918513e-02 | 1.228 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 6.016058e-02 | 1.221 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 6.052064e-02 | 1.218 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.247750e-02 | 1.204 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 6.304218e-02 | 1.200 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.310780e-02 | 1.200 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.339550e-02 | 1.198 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 6.416395e-02 | 1.193 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 6.492943e-02 | 1.188 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.737399e-02 | 1.172 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 6.774183e-02 | 1.169 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 7.150540e-02 | 1.146 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 7.253798e-02 | 1.139 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 7.253798e-02 | 1.139 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 7.253798e-02 | 1.139 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.253798e-02 | 1.139 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 9.101164e-02 | 1.041 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 9.101164e-02 | 1.041 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 7.672694e-02 | 1.115 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 9.176796e-02 | 1.037 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 9.176796e-02 | 1.037 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 9.176796e-02 | 1.037 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 9.176796e-02 | 1.037 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 9.176796e-02 | 1.037 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 8.659732e-02 | 1.062 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 7.971079e-02 | 1.098 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.223591e-02 | 1.085 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.499063e-02 | 1.071 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.268893e-02 | 1.139 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.971079e-02 | 1.098 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 7.301138e-02 | 1.137 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 9.176796e-02 | 1.037 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 9.113081e-02 | 1.040 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 8.525966e-02 | 1.069 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 9.405658e-02 | 1.027 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 7.672694e-02 | 1.115 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 7.301138e-02 | 1.137 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 9.005077e-02 | 1.046 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 8.009939e-02 | 1.096 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.450389e-02 | 1.128 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.301138e-02 | 1.137 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 7.380195e-02 | 1.132 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 8.223591e-02 | 1.085 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 7.577965e-02 | 1.120 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 8.795082e-02 | 1.056 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.659732e-02 | 1.062 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 8.773348e-02 | 1.057 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 7.809976e-02 | 1.107 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 7.672694e-02 | 1.115 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 9.412815e-02 | 1.026 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 8.499063e-02 | 1.071 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.380195e-02 | 1.132 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.689535e-02 | 1.014 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 9.893553e-02 | 1.005 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 9.893553e-02 | 1.005 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 9.921685e-02 | 1.003 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 9.964959e-02 | 1.002 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 9.964959e-02 | 1.002 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.964959e-02 | 1.002 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.003036e-01 | 0.999 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.003036e-01 | 0.999 | 0 | 0 |
| Defective SFTPA2 causes IPF | R-HSA-5687868 | 1.003036e-01 | 0.999 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.003036e-01 | 0.999 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.003036e-01 | 0.999 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.003036e-01 | 0.999 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.003036e-01 | 0.999 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.003036e-01 | 0.999 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.003036e-01 | 0.999 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.019203e-01 | 0.992 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.019203e-01 | 0.992 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.019203e-01 | 0.992 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.049710e-01 | 0.979 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.054438e-01 | 0.977 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.062293e-01 | 0.974 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 1.080942e-01 | 0.966 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.080942e-01 | 0.966 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.087210e-01 | 0.964 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 1.090474e-01 | 0.962 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.090474e-01 | 0.962 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.090474e-01 | 0.962 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.090474e-01 | 0.962 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.091300e-01 | 0.962 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.118860e-01 | 0.951 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 1.121429e-01 | 0.950 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.124533e-01 | 0.949 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.124533e-01 | 0.949 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.128170e-01 | 0.948 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.141201e-01 | 0.943 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.156767e-01 | 0.937 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.158223e-01 | 0.936 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.171766e-01 | 0.931 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.177382e-01 | 0.929 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 1.177382e-01 | 0.929 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.190549e-01 | 0.924 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.199847e-01 | 0.921 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.201461e-01 | 0.920 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 1.201461e-01 | 0.920 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 1.222649e-01 | 0.913 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.226923e-01 | 0.911 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.227965e-01 | 0.911 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.235276e-01 | 0.908 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.235276e-01 | 0.908 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.235276e-01 | 0.908 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.237197e-01 | 0.908 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.243932e-01 | 0.905 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.256209e-01 | 0.901 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 1.270195e-01 | 0.896 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 1.332525e-01 | 0.875 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.332525e-01 | 0.875 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.332525e-01 | 0.875 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.337248e-01 | 0.874 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.354760e-01 | 0.868 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.355969e-01 | 0.868 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.355969e-01 | 0.868 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.355969e-01 | 0.868 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.355969e-01 | 0.868 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.360863e-01 | 0.866 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.362334e-01 | 0.866 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 1.362334e-01 | 0.866 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.362334e-01 | 0.866 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 1.905516e-01 | 0.720 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.905516e-01 | 0.720 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 1.905516e-01 | 0.720 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.905516e-01 | 0.720 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 1.905516e-01 | 0.720 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 1.905516e-01 | 0.720 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 1.905516e-01 | 0.720 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 1.905516e-01 | 0.720 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.905516e-01 | 0.720 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.905516e-01 | 0.720 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.697531e-01 | 0.770 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.602012e-01 | 0.795 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.602012e-01 | 0.795 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.860246e-01 | 0.730 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.860246e-01 | 0.730 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.860246e-01 | 0.730 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.442526e-01 | 0.841 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 1.844117e-01 | 0.734 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 1.606374e-01 | 0.794 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.405902e-01 | 0.852 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.405902e-01 | 0.852 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.057178e-01 | 0.687 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.696110e-01 | 0.771 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.696110e-01 | 0.771 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.479679e-01 | 0.830 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.479679e-01 | 0.830 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.008816e-01 | 0.697 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 1.644421e-01 | 0.784 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.884616e-01 | 0.725 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.640375e-01 | 0.785 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.982060e-01 | 0.703 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.382865e-01 | 0.859 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.382865e-01 | 0.859 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.564543e-01 | 0.806 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.824402e-01 | 0.739 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 1.644421e-01 | 0.784 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.777013e-01 | 0.750 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.408339e-01 | 0.851 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 1.609802e-01 | 0.793 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.946434e-01 | 0.711 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.442526e-01 | 0.841 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 2.028732e-01 | 0.693 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.764721e-01 | 0.753 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 1.860246e-01 | 0.730 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.606374e-01 | 0.794 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 1.744873e-01 | 0.758 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 1.744873e-01 | 0.758 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.778194e-01 | 0.750 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.460236e-01 | 0.836 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.919984e-01 | 0.717 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.632699e-01 | 0.787 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.561639e-01 | 0.806 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.638859e-01 | 0.785 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.057178e-01 | 0.687 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.849857e-01 | 0.733 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 2.008816e-01 | 0.697 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 1.376584e-01 | 0.861 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.771151e-01 | 0.752 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 1.778194e-01 | 0.750 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.466319e-01 | 0.834 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.696110e-01 | 0.771 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 1.860246e-01 | 0.730 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.860246e-01 | 0.730 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.638859e-01 | 0.785 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.956544e-01 | 0.709 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.744873e-01 | 0.758 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.000039e-01 | 0.699 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.587228e-01 | 0.799 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.057290e-01 | 0.687 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 1.405472e-01 | 0.852 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.470389e-01 | 0.833 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.602012e-01 | 0.795 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.549473e-01 | 0.810 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.031735e-01 | 0.692 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.897356e-01 | 0.722 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.609802e-01 | 0.793 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.491896e-01 | 0.826 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.956544e-01 | 0.709 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 1.834595e-01 | 0.736 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 1.849857e-01 | 0.733 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 1.441720e-01 | 0.841 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 1.956544e-01 | 0.709 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.460236e-01 | 0.836 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 1.697531e-01 | 0.770 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 2.076548e-01 | 0.683 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.076548e-01 | 0.683 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 2.076548e-01 | 0.683 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 2.076548e-01 | 0.683 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.076548e-01 | 0.683 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.076548e-01 | 0.683 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.076548e-01 | 0.683 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 2.076548e-01 | 0.683 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 2.122650e-01 | 0.673 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.128305e-01 | 0.672 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 2.128305e-01 | 0.672 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 2.128305e-01 | 0.672 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 2.128305e-01 | 0.672 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.128305e-01 | 0.672 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.128355e-01 | 0.672 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.140763e-01 | 0.669 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 2.165441e-01 | 0.664 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 2.165441e-01 | 0.664 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 2.165441e-01 | 0.664 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 2.220417e-01 | 0.654 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.274244e-01 | 0.643 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.276903e-01 | 0.643 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.276903e-01 | 0.643 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.276903e-01 | 0.643 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.278348e-01 | 0.642 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.287565e-01 | 0.641 | 0 | 0 |
| Translation | R-HSA-72766 | 2.304905e-01 | 0.637 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.328817e-01 | 0.633 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 2.328817e-01 | 0.633 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.328817e-01 | 0.633 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.330168e-01 | 0.633 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 2.340593e-01 | 0.631 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.340593e-01 | 0.631 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.340593e-01 | 0.631 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 2.359529e-01 | 0.627 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.388084e-01 | 0.622 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.403923e-01 | 0.619 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.403923e-01 | 0.619 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 2.403923e-01 | 0.619 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 2.403923e-01 | 0.619 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.403923e-01 | 0.619 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.403923e-01 | 0.619 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.430313e-01 | 0.614 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 2.717518e-01 | 0.566 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 2.717518e-01 | 0.566 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.717518e-01 | 0.566 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 2.717518e-01 | 0.566 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 2.717518e-01 | 0.566 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 2.717518e-01 | 0.566 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.717518e-01 | 0.566 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 2.717518e-01 | 0.566 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 2.717518e-01 | 0.566 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.717518e-01 | 0.566 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.717518e-01 | 0.566 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.448106e-01 | 0.462 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.448106e-01 | 0.462 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.448106e-01 | 0.462 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.448106e-01 | 0.462 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.448106e-01 | 0.462 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.448106e-01 | 0.462 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.448106e-01 | 0.462 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.463097e-01 | 0.609 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.851858e-01 | 0.545 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 2.851858e-01 | 0.545 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.851858e-01 | 0.545 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 2.851858e-01 | 0.545 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 2.851858e-01 | 0.545 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 2.851858e-01 | 0.545 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 4.105439e-01 | 0.387 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 4.105439e-01 | 0.387 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 4.105439e-01 | 0.387 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.105439e-01 | 0.387 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 4.105439e-01 | 0.387 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.105439e-01 | 0.387 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.105439e-01 | 0.387 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 3.238501e-01 | 0.490 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.238501e-01 | 0.490 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.238501e-01 | 0.490 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.502161e-01 | 0.602 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 3.619540e-01 | 0.441 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 4.696859e-01 | 0.328 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 4.696859e-01 | 0.328 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 4.696859e-01 | 0.328 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.696859e-01 | 0.328 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 4.696859e-01 | 0.328 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 3.255436e-01 | 0.487 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 3.255436e-01 | 0.487 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 3.255436e-01 | 0.487 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.964849e-01 | 0.528 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.992211e-01 | 0.399 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 3.541374e-01 | 0.451 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 3.541374e-01 | 0.451 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 3.200153e-01 | 0.495 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.200153e-01 | 0.495 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 2.642469e-01 | 0.578 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 3.825717e-01 | 0.417 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.354359e-01 | 0.361 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.354359e-01 | 0.361 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.354359e-01 | 0.361 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.354359e-01 | 0.361 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.330868e-01 | 0.477 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.330868e-01 | 0.477 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.673726e-01 | 0.435 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.228991e-01 | 0.491 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 3.910181e-01 | 0.408 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.704346e-01 | 0.328 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.704346e-01 | 0.328 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 4.704346e-01 | 0.328 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 4.704346e-01 | 0.328 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.597972e-01 | 0.444 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.597972e-01 | 0.444 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.950294e-01 | 0.403 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.783540e-01 | 0.422 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 3.783540e-01 | 0.422 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.783540e-01 | 0.422 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.134587e-01 | 0.384 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.134587e-01 | 0.384 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 3.692123e-01 | 0.433 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 4.564228e-01 | 0.341 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.835602e-01 | 0.316 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.835602e-01 | 0.316 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.485070e-01 | 0.348 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.886151e-01 | 0.311 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 3.809313e-01 | 0.419 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 2.671202e-01 | 0.573 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 2.674910e-01 | 0.573 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.075701e-01 | 0.512 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 3.537025e-01 | 0.451 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 3.783540e-01 | 0.422 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 3.783540e-01 | 0.422 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.200153e-01 | 0.495 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.412974e-01 | 0.467 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.524070e-01 | 0.598 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.299252e-01 | 0.482 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.591734e-01 | 0.586 | 0 | 0 |
| Extrinsic Pathway of Fibrin Clot Formation | R-HSA-140834 | 4.696859e-01 | 0.328 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 3.299252e-01 | 0.482 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.132261e-01 | 0.504 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.354359e-01 | 0.361 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.619540e-01 | 0.441 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 3.255436e-01 | 0.487 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.316129e-01 | 0.365 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 3.880037e-01 | 0.411 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.731837e-01 | 0.564 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 2.721773e-01 | 0.565 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 2.642469e-01 | 0.578 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 2.642469e-01 | 0.578 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.783540e-01 | 0.422 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 4.835602e-01 | 0.316 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 3.541374e-01 | 0.451 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.886151e-01 | 0.311 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 2.717518e-01 | 0.566 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 3.619540e-01 | 0.441 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.696859e-01 | 0.328 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.687751e-01 | 0.571 | 0 | 0 |
| PKA activation | R-HSA-163615 | 4.384429e-01 | 0.358 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 4.705535e-01 | 0.327 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 3.138628e-01 | 0.503 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 3.436758e-01 | 0.464 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.573980e-01 | 0.447 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 3.965253e-01 | 0.402 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.953955e-01 | 0.530 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.953955e-01 | 0.530 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.953955e-01 | 0.530 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.953955e-01 | 0.530 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.145311e-01 | 0.382 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 4.361068e-01 | 0.360 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.765284e-01 | 0.322 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.813467e-01 | 0.551 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.316129e-01 | 0.365 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.238501e-01 | 0.490 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 2.810216e-01 | 0.551 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.684956e-01 | 0.571 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.731837e-01 | 0.564 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.783540e-01 | 0.422 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 4.292200e-01 | 0.367 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.659989e-01 | 0.332 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.121208e-01 | 0.506 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.511230e-01 | 0.600 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.410876e-01 | 0.467 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.255436e-01 | 0.487 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 3.409433e-01 | 0.467 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.809093e-01 | 0.551 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 4.105439e-01 | 0.387 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 4.105439e-01 | 0.387 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 4.696859e-01 | 0.328 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 4.696859e-01 | 0.328 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 3.673726e-01 | 0.435 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.092271e-01 | 0.510 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.992211e-01 | 0.399 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 3.619540e-01 | 0.441 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 3.825717e-01 | 0.417 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.274185e-01 | 0.485 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.138628e-01 | 0.503 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.704992e-01 | 0.431 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.953955e-01 | 0.530 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.950294e-01 | 0.403 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.446758e-01 | 0.611 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.411536e-01 | 0.355 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.564692e-01 | 0.341 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.224286e-01 | 0.492 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.717518e-01 | 0.566 | 0 | 0 |
| Interleukin-33 signaling | R-HSA-9014843 | 3.448106e-01 | 0.462 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.448106e-01 | 0.462 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.448106e-01 | 0.462 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 3.448106e-01 | 0.462 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 2.851858e-01 | 0.545 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.105439e-01 | 0.387 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.105439e-01 | 0.387 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.238501e-01 | 0.490 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 3.238501e-01 | 0.490 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.696859e-01 | 0.328 | 0 | 0 |
| GABA synthesis | R-HSA-888568 | 4.696859e-01 | 0.328 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 2.964849e-01 | 0.528 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 3.992211e-01 | 0.399 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 3.541374e-01 | 0.451 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 3.200153e-01 | 0.495 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 2.922591e-01 | 0.534 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.825717e-01 | 0.417 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 4.704346e-01 | 0.328 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 4.384429e-01 | 0.358 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 4.384429e-01 | 0.358 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 3.348905e-01 | 0.475 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.137412e-01 | 0.503 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.976540e-01 | 0.400 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.835602e-01 | 0.316 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 3.395203e-01 | 0.469 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 4.705535e-01 | 0.327 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.548522e-01 | 0.594 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.761567e-01 | 0.322 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.712741e-01 | 0.567 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.194090e-01 | 0.496 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.658770e-01 | 0.575 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.274185e-01 | 0.485 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.803513e-01 | 0.552 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 2.717018e-01 | 0.566 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.728036e-01 | 0.325 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.885166e-01 | 0.311 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 2.851858e-01 | 0.545 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 3.238501e-01 | 0.490 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 4.696859e-01 | 0.328 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 3.255436e-01 | 0.487 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 4.378367e-01 | 0.359 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.436715e-01 | 0.353 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 3.743697e-01 | 0.427 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.656602e-01 | 0.332 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.537025e-01 | 0.451 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.463097e-01 | 0.609 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.105439e-01 | 0.387 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.619540e-01 | 0.441 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.992211e-01 | 0.399 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 3.910181e-01 | 0.408 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.704346e-01 | 0.328 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.597972e-01 | 0.444 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.783540e-01 | 0.422 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.384748e-01 | 0.470 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.223203e-01 | 0.374 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 3.825887e-01 | 0.417 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.761567e-01 | 0.322 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.761567e-01 | 0.322 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 3.255436e-01 | 0.487 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.992211e-01 | 0.399 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.354359e-01 | 0.361 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.378367e-01 | 0.359 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.608669e-01 | 0.336 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 4.886006e-01 | 0.311 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 3.255436e-01 | 0.487 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 3.691774e-01 | 0.433 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.886151e-01 | 0.311 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.886151e-01 | 0.311 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.105439e-01 | 0.387 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 3.619540e-01 | 0.441 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 3.541374e-01 | 0.451 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.950294e-01 | 0.403 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.686913e-01 | 0.433 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 3.255436e-01 | 0.487 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.502161e-01 | 0.602 | 0 | 0 |
| Toxicity of tetanus toxin (tetX) | R-HSA-5250982 | 4.696859e-01 | 0.328 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 4.354359e-01 | 0.361 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 3.597972e-01 | 0.444 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 4.361068e-01 | 0.360 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.046480e-01 | 0.516 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.502161e-01 | 0.602 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 4.339461e-01 | 0.363 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.992211e-01 | 0.399 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.354359e-01 | 0.361 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.378367e-01 | 0.359 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 4.354359e-01 | 0.361 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.964849e-01 | 0.528 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 2.464040e-01 | 0.608 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 4.916119e-01 | 0.308 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 4.922772e-01 | 0.308 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.922772e-01 | 0.308 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.922772e-01 | 0.308 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 4.922772e-01 | 0.308 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 4.963816e-01 | 0.304 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 4.985121e-01 | 0.302 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.040967e-01 | 0.297 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.040967e-01 | 0.297 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.040967e-01 | 0.297 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 5.040967e-01 | 0.297 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 5.040967e-01 | 0.297 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 5.040967e-01 | 0.297 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 5.040967e-01 | 0.297 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 5.040967e-01 | 0.297 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 5.040967e-01 | 0.297 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 5.040967e-01 | 0.297 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 5.040967e-01 | 0.297 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 5.040967e-01 | 0.297 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 5.058617e-01 | 0.296 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.064733e-01 | 0.295 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 5.077430e-01 | 0.294 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 5.109412e-01 | 0.292 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 5.109412e-01 | 0.292 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 5.159440e-01 | 0.287 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 5.182202e-01 | 0.285 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 5.195135e-01 | 0.284 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.195135e-01 | 0.284 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 5.200706e-01 | 0.284 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 5.221211e-01 | 0.282 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 5.228971e-01 | 0.282 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.228971e-01 | 0.282 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 5.228971e-01 | 0.282 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.228971e-01 | 0.282 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.228971e-01 | 0.282 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.228971e-01 | 0.282 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.228971e-01 | 0.282 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.228971e-01 | 0.282 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 5.228971e-01 | 0.282 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 5.228971e-01 | 0.282 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.228971e-01 | 0.282 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.228971e-01 | 0.282 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 5.228971e-01 | 0.282 | 0 | 0 |
| Interleukin-36 pathway | R-HSA-9014826 | 5.228971e-01 | 0.282 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.228971e-01 | 0.282 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.228971e-01 | 0.282 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.228971e-01 | 0.282 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 5.228971e-01 | 0.282 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.228971e-01 | 0.282 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.228971e-01 | 0.282 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 5.228971e-01 | 0.282 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 5.240996e-01 | 0.281 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 5.240996e-01 | 0.281 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.256547e-01 | 0.279 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.256547e-01 | 0.279 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 5.275852e-01 | 0.278 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 5.277228e-01 | 0.278 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.277228e-01 | 0.278 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 5.277228e-01 | 0.278 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.342937e-01 | 0.272 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 5.363381e-01 | 0.271 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.363381e-01 | 0.271 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 5.363381e-01 | 0.271 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 5.363381e-01 | 0.271 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.414674e-01 | 0.266 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 5.414674e-01 | 0.266 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 5.425866e-01 | 0.266 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 5.434286e-01 | 0.265 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 5.434286e-01 | 0.265 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 5.491010e-01 | 0.260 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 5.491010e-01 | 0.260 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 5.491010e-01 | 0.260 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.519463e-01 | 0.258 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 5.540611e-01 | 0.256 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.540611e-01 | 0.256 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.540611e-01 | 0.256 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 5.579251e-01 | 0.253 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.671050e-01 | 0.246 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 5.671050e-01 | 0.246 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.671050e-01 | 0.246 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.671050e-01 | 0.246 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 5.671050e-01 | 0.246 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 5.671050e-01 | 0.246 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 5.671050e-01 | 0.246 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 5.678531e-01 | 0.246 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 5.678531e-01 | 0.246 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.678531e-01 | 0.246 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 5.678531e-01 | 0.246 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 5.683665e-01 | 0.245 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.699599e-01 | 0.244 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.700499e-01 | 0.244 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.704396e-01 | 0.244 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.707719e-01 | 0.244 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 5.707719e-01 | 0.244 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 5.707719e-01 | 0.244 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 5.707719e-01 | 0.244 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.707719e-01 | 0.244 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 5.707719e-01 | 0.244 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 5.707719e-01 | 0.244 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 5.707719e-01 | 0.244 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.707719e-01 | 0.244 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 5.707719e-01 | 0.244 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 5.707719e-01 | 0.244 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 5.707719e-01 | 0.244 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 5.707719e-01 | 0.244 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 5.707719e-01 | 0.244 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 5.707719e-01 | 0.244 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 5.707719e-01 | 0.244 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 5.707719e-01 | 0.244 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 5.707719e-01 | 0.244 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 5.725568e-01 | 0.242 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.725568e-01 | 0.242 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 5.725568e-01 | 0.242 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 5.725568e-01 | 0.242 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.769811e-01 | 0.239 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 5.781617e-01 | 0.238 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.809804e-01 | 0.236 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 5.831758e-01 | 0.234 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 5.902685e-01 | 0.229 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 5.902685e-01 | 0.229 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.902685e-01 | 0.229 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 5.906435e-01 | 0.229 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.906435e-01 | 0.229 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.917912e-01 | 0.228 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.933575e-01 | 0.227 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.951620e-01 | 0.225 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 5.963688e-01 | 0.224 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 5.963688e-01 | 0.224 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.963688e-01 | 0.224 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 5.963688e-01 | 0.224 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 5.968290e-01 | 0.224 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.971042e-01 | 0.224 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.011882e-01 | 0.221 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.011882e-01 | 0.221 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.011882e-01 | 0.221 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.079072e-01 | 0.216 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 6.079072e-01 | 0.216 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 6.082711e-01 | 0.216 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 6.083002e-01 | 0.216 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 6.100012e-01 | 0.215 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 6.100012e-01 | 0.215 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 6.100012e-01 | 0.215 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 6.100012e-01 | 0.215 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 6.100012e-01 | 0.215 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 6.130453e-01 | 0.213 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.138453e-01 | 0.212 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 6.138453e-01 | 0.212 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.138453e-01 | 0.212 | 0 | 0 |
| Defective CYP11A1 causes AICSR | R-HSA-5579026 | 6.138453e-01 | 0.212 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 6.138453e-01 | 0.212 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 6.138453e-01 | 0.212 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 6.138453e-01 | 0.212 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 6.138453e-01 | 0.212 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.138453e-01 | 0.212 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.138453e-01 | 0.212 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 6.138453e-01 | 0.212 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.138453e-01 | 0.212 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.138453e-01 | 0.212 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.138453e-01 | 0.212 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.138453e-01 | 0.212 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.138453e-01 | 0.212 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 6.142071e-01 | 0.212 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.142071e-01 | 0.212 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.204769e-01 | 0.207 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.241212e-01 | 0.205 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.241212e-01 | 0.205 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.241212e-01 | 0.205 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.241212e-01 | 0.205 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 6.241212e-01 | 0.205 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.241212e-01 | 0.205 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 6.255088e-01 | 0.204 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 6.255088e-01 | 0.204 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 6.255088e-01 | 0.204 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 6.291374e-01 | 0.201 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 6.291374e-01 | 0.201 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.360881e-01 | 0.196 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.360881e-01 | 0.196 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 6.360881e-01 | 0.196 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 6.383298e-01 | 0.195 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 6.398307e-01 | 0.194 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 6.422544e-01 | 0.192 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 6.476611e-01 | 0.189 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 6.476611e-01 | 0.189 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.476611e-01 | 0.189 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 6.476611e-01 | 0.189 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 6.493767e-01 | 0.188 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.503708e-01 | 0.187 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.503708e-01 | 0.187 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.503708e-01 | 0.187 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.503708e-01 | 0.187 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.525985e-01 | 0.185 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.525985e-01 | 0.185 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.525985e-01 | 0.185 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 6.525985e-01 | 0.185 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.525985e-01 | 0.185 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.525985e-01 | 0.185 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 6.525985e-01 | 0.185 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 6.525985e-01 | 0.185 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 6.525985e-01 | 0.185 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.525985e-01 | 0.185 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.525985e-01 | 0.185 | 0 | 0 |
| Electron transport from NADPH to Ferredoxin | R-HSA-2395516 | 6.525985e-01 | 0.185 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.525985e-01 | 0.185 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 6.525985e-01 | 0.185 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.525985e-01 | 0.185 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.525985e-01 | 0.185 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 6.525985e-01 | 0.185 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.570863e-01 | 0.182 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.570863e-01 | 0.182 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.570863e-01 | 0.182 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.570863e-01 | 0.182 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.572546e-01 | 0.182 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 6.587587e-01 | 0.181 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.604936e-01 | 0.180 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 6.655605e-01 | 0.177 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.655605e-01 | 0.177 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.655605e-01 | 0.177 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 6.687061e-01 | 0.175 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 6.743100e-01 | 0.171 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.751398e-01 | 0.171 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.751398e-01 | 0.171 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.751398e-01 | 0.171 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 6.751398e-01 | 0.171 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 6.751398e-01 | 0.171 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 6.771967e-01 | 0.169 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 6.771967e-01 | 0.169 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 6.771967e-01 | 0.169 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 6.771967e-01 | 0.169 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 6.771967e-01 | 0.169 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.774048e-01 | 0.169 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 6.828279e-01 | 0.166 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 6.828279e-01 | 0.166 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.872326e-01 | 0.163 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 6.874647e-01 | 0.163 | 0 | 0 |
| RSK activation | R-HSA-444257 | 6.874647e-01 | 0.163 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 6.874647e-01 | 0.163 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 6.874647e-01 | 0.163 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.874647e-01 | 0.163 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.874647e-01 | 0.163 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.874647e-01 | 0.163 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 6.874647e-01 | 0.163 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.874647e-01 | 0.163 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 6.874647e-01 | 0.163 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 6.896035e-01 | 0.161 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 6.928818e-01 | 0.159 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 6.928818e-01 | 0.159 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.964203e-01 | 0.157 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 6.984609e-01 | 0.156 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.984609e-01 | 0.156 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.984609e-01 | 0.156 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 6.984609e-01 | 0.156 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 6.984609e-01 | 0.156 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 6.984609e-01 | 0.156 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 6.984609e-01 | 0.156 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.991708e-01 | 0.155 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 6.994590e-01 | 0.155 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.096826e-01 | 0.149 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.101252e-01 | 0.149 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.131871e-01 | 0.147 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.131871e-01 | 0.147 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 7.147632e-01 | 0.146 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.147632e-01 | 0.146 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 7.147632e-01 | 0.146 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.147632e-01 | 0.146 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 7.154530e-01 | 0.145 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 7.154530e-01 | 0.145 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 7.154530e-01 | 0.145 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 7.154530e-01 | 0.145 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 7.176883e-01 | 0.144 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.186982e-01 | 0.143 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.186982e-01 | 0.143 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.188334e-01 | 0.143 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 7.188334e-01 | 0.143 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 7.188334e-01 | 0.143 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 7.188334e-01 | 0.143 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.188334e-01 | 0.143 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.188334e-01 | 0.143 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 7.188334e-01 | 0.143 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.188334e-01 | 0.143 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.188334e-01 | 0.143 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.188334e-01 | 0.143 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.188334e-01 | 0.143 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 7.188334e-01 | 0.143 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.188334e-01 | 0.143 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.188334e-01 | 0.143 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 7.188334e-01 | 0.143 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 7.203752e-01 | 0.142 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 7.203752e-01 | 0.142 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 7.203752e-01 | 0.142 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 7.203752e-01 | 0.142 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.203752e-01 | 0.142 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.210625e-01 | 0.142 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.277674e-01 | 0.138 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.307106e-01 | 0.136 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.308118e-01 | 0.136 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 7.308118e-01 | 0.136 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.308118e-01 | 0.136 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.322362e-01 | 0.135 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.322362e-01 | 0.135 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.322362e-01 | 0.135 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.324963e-01 | 0.135 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 7.357062e-01 | 0.133 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 7.368989e-01 | 0.133 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.397158e-01 | 0.131 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 7.397158e-01 | 0.131 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.409301e-01 | 0.130 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.409301e-01 | 0.130 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 7.470554e-01 | 0.127 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.470554e-01 | 0.127 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 7.470554e-01 | 0.127 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.470554e-01 | 0.127 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 7.470554e-01 | 0.127 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 7.470554e-01 | 0.127 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 7.470554e-01 | 0.127 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 7.470554e-01 | 0.127 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.470554e-01 | 0.127 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.470554e-01 | 0.127 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 7.470554e-01 | 0.127 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 7.470554e-01 | 0.127 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 7.478783e-01 | 0.126 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.488542e-01 | 0.126 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 7.488542e-01 | 0.126 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.583253e-01 | 0.120 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.596451e-01 | 0.119 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.601777e-01 | 0.119 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.601777e-01 | 0.119 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.601777e-01 | 0.119 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 7.601777e-01 | 0.119 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 7.601777e-01 | 0.119 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 7.646352e-01 | 0.117 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 7.670402e-01 | 0.115 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.670842e-01 | 0.115 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 7.709130e-01 | 0.113 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 7.709130e-01 | 0.113 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.709130e-01 | 0.113 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.713865e-01 | 0.113 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.713865e-01 | 0.113 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 7.724216e-01 | 0.112 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.724460e-01 | 0.112 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 7.724460e-01 | 0.112 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.724460e-01 | 0.112 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.724460e-01 | 0.112 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 7.724460e-01 | 0.112 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.724460e-01 | 0.112 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.724460e-01 | 0.112 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 7.724460e-01 | 0.112 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 7.724460e-01 | 0.112 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.774702e-01 | 0.109 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.781732e-01 | 0.109 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 7.781732e-01 | 0.109 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.781732e-01 | 0.109 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.781732e-01 | 0.109 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.781732e-01 | 0.109 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.795998e-01 | 0.108 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 7.860227e-01 | 0.105 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.860227e-01 | 0.105 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 7.920225e-01 | 0.101 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 7.937710e-01 | 0.100 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.949740e-01 | 0.100 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.949740e-01 | 0.100 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 7.949740e-01 | 0.100 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.949740e-01 | 0.100 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 7.949740e-01 | 0.100 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.949740e-01 | 0.100 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 7.952893e-01 | 0.099 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 7.952893e-01 | 0.099 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 7.952893e-01 | 0.099 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 7.952893e-01 | 0.099 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 7.983187e-01 | 0.098 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.983187e-01 | 0.098 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.983187e-01 | 0.098 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.020021e-01 | 0.096 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 8.049702e-01 | 0.094 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 8.049702e-01 | 0.094 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 8.049702e-01 | 0.094 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.071737e-01 | 0.093 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.071737e-01 | 0.093 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.071737e-01 | 0.093 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 8.071737e-01 | 0.093 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 8.071737e-01 | 0.093 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.071737e-01 | 0.093 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 8.100374e-01 | 0.091 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 8.100374e-01 | 0.091 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 8.100374e-01 | 0.091 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 8.100374e-01 | 0.091 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 8.106386e-01 | 0.091 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.123979e-01 | 0.090 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 8.155308e-01 | 0.089 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 8.158407e-01 | 0.088 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.158407e-01 | 0.088 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 8.158407e-01 | 0.088 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 8.158407e-01 | 0.088 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.158407e-01 | 0.088 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 8.158407e-01 | 0.088 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.158407e-01 | 0.088 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.158407e-01 | 0.088 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.158407e-01 | 0.088 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 8.158407e-01 | 0.088 | 0 | 0 |
| Metallothioneins bind metals | R-HSA-5661231 | 8.158407e-01 | 0.088 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.158407e-01 | 0.088 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.195174e-01 | 0.086 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 8.195174e-01 | 0.086 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 8.198340e-01 | 0.086 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.198340e-01 | 0.086 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 8.198340e-01 | 0.086 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 8.211937e-01 | 0.086 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.252258e-01 | 0.083 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 8.252258e-01 | 0.083 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 8.252258e-01 | 0.083 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.275457e-01 | 0.082 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.301773e-01 | 0.081 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 8.307785e-01 | 0.081 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 8.318033e-01 | 0.080 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.343300e-01 | 0.079 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.343300e-01 | 0.079 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.343300e-01 | 0.079 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 8.343300e-01 | 0.079 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.343300e-01 | 0.079 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.343300e-01 | 0.079 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 8.343300e-01 | 0.079 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 8.343300e-01 | 0.079 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.343300e-01 | 0.079 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.348830e-01 | 0.078 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 8.348830e-01 | 0.078 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 8.387938e-01 | 0.076 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.387938e-01 | 0.076 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.429223e-01 | 0.074 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 8.430367e-01 | 0.074 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 8.430367e-01 | 0.074 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 8.509639e-01 | 0.070 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.509639e-01 | 0.070 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.509639e-01 | 0.070 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 8.509639e-01 | 0.070 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.509639e-01 | 0.070 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.509639e-01 | 0.070 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.509639e-01 | 0.070 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 8.509639e-01 | 0.070 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.509639e-01 | 0.070 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.509639e-01 | 0.070 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.509639e-01 | 0.070 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 8.514003e-01 | 0.070 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 8.514003e-01 | 0.070 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 8.514003e-01 | 0.070 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.514003e-01 | 0.070 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 8.514003e-01 | 0.070 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 8.514494e-01 | 0.070 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.526603e-01 | 0.069 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.536352e-01 | 0.069 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 8.596074e-01 | 0.066 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 8.596074e-01 | 0.066 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 8.605205e-01 | 0.065 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.631016e-01 | 0.064 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.631016e-01 | 0.064 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.631016e-01 | 0.064 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.631016e-01 | 0.064 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 8.631937e-01 | 0.064 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 8.636030e-01 | 0.064 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.636030e-01 | 0.064 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.645983e-01 | 0.063 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.659286e-01 | 0.063 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 8.659286e-01 | 0.063 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.659286e-01 | 0.063 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.659286e-01 | 0.063 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 8.659286e-01 | 0.063 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.659286e-01 | 0.063 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 8.659286e-01 | 0.063 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 8.659286e-01 | 0.063 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.659286e-01 | 0.063 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.659286e-01 | 0.063 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 8.659286e-01 | 0.063 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.659286e-01 | 0.063 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 8.688154e-01 | 0.061 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 8.704428e-01 | 0.060 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.729685e-01 | 0.059 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 8.729685e-01 | 0.059 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.739522e-01 | 0.059 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 8.793915e-01 | 0.056 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.793915e-01 | 0.056 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 8.793915e-01 | 0.056 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.793915e-01 | 0.056 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 8.793915e-01 | 0.056 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 8.793915e-01 | 0.056 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.793915e-01 | 0.056 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.793915e-01 | 0.056 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.793915e-01 | 0.056 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 8.793915e-01 | 0.056 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 8.817600e-01 | 0.055 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 8.840049e-01 | 0.054 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 8.840049e-01 | 0.054 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.840049e-01 | 0.054 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 8.840049e-01 | 0.054 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 8.840049e-01 | 0.054 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.840049e-01 | 0.054 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 8.857568e-01 | 0.053 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.857568e-01 | 0.053 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 8.900052e-01 | 0.051 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 8.900052e-01 | 0.051 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 8.902890e-01 | 0.050 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 8.902890e-01 | 0.050 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 8.902890e-01 | 0.050 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 8.915032e-01 | 0.050 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 8.915032e-01 | 0.050 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.915032e-01 | 0.050 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.915032e-01 | 0.050 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.915032e-01 | 0.050 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.915032e-01 | 0.050 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 8.915032e-01 | 0.050 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 8.915918e-01 | 0.050 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 8.942602e-01 | 0.049 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 8.942602e-01 | 0.049 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 8.963031e-01 | 0.048 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.996321e-01 | 0.046 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.019179e-01 | 0.045 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.019179e-01 | 0.045 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.019179e-01 | 0.045 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 9.020330e-01 | 0.045 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 9.023993e-01 | 0.045 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 9.023993e-01 | 0.045 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.023993e-01 | 0.045 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.023993e-01 | 0.045 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.023993e-01 | 0.045 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.023993e-01 | 0.045 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 9.023993e-01 | 0.045 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.049655e-01 | 0.043 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.051845e-01 | 0.043 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 9.085550e-01 | 0.042 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 9.098732e-01 | 0.041 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.121708e-01 | 0.040 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.122017e-01 | 0.040 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 9.122017e-01 | 0.040 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.122017e-01 | 0.040 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 9.122017e-01 | 0.040 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.122017e-01 | 0.040 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.140401e-01 | 0.039 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 9.172205e-01 | 0.038 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.172205e-01 | 0.038 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.172205e-01 | 0.038 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.172780e-01 | 0.037 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.210201e-01 | 0.036 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.210201e-01 | 0.036 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 9.210201e-01 | 0.036 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.210201e-01 | 0.036 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.210201e-01 | 0.036 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.210201e-01 | 0.036 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 9.210201e-01 | 0.036 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.210201e-01 | 0.036 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.210201e-01 | 0.036 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.210201e-01 | 0.036 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.210201e-01 | 0.036 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.239703e-01 | 0.034 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 9.239703e-01 | 0.034 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.240017e-01 | 0.034 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.240017e-01 | 0.034 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 9.241481e-01 | 0.034 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.279015e-01 | 0.032 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.289533e-01 | 0.032 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.289533e-01 | 0.032 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.289533e-01 | 0.032 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.289533e-01 | 0.032 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.289533e-01 | 0.032 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.289533e-01 | 0.032 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 9.289533e-01 | 0.032 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.289533e-01 | 0.032 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.289533e-01 | 0.032 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.302564e-01 | 0.031 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.302564e-01 | 0.031 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.302564e-01 | 0.031 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.302564e-01 | 0.031 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.326881e-01 | 0.030 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.331869e-01 | 0.030 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.350002e-01 | 0.029 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.360901e-01 | 0.029 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.360901e-01 | 0.029 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.360901e-01 | 0.029 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.360901e-01 | 0.029 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.360901e-01 | 0.029 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.360901e-01 | 0.029 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.370723e-01 | 0.028 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.371652e-01 | 0.028 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.371851e-01 | 0.028 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 9.371851e-01 | 0.028 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 9.404130e-01 | 0.027 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.410031e-01 | 0.026 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.413332e-01 | 0.026 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 9.413332e-01 | 0.026 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.413332e-01 | 0.026 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.413332e-01 | 0.026 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 9.425103e-01 | 0.026 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.425103e-01 | 0.026 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.443718e-01 | 0.025 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.449433e-01 | 0.025 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.462236e-01 | 0.024 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.480643e-01 | 0.023 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.482859e-01 | 0.023 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.482859e-01 | 0.023 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.482859e-01 | 0.023 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.482859e-01 | 0.023 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.482859e-01 | 0.023 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.507238e-01 | 0.022 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.507238e-01 | 0.022 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.525666e-01 | 0.021 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.532636e-01 | 0.021 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.534816e-01 | 0.021 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.534816e-01 | 0.021 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.534816e-01 | 0.021 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.534816e-01 | 0.021 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.534816e-01 | 0.021 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.534816e-01 | 0.021 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.534816e-01 | 0.021 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.534816e-01 | 0.021 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 9.534816e-01 | 0.021 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.548630e-01 | 0.020 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.548630e-01 | 0.020 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.569902e-01 | 0.019 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.577258e-01 | 0.019 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 9.581555e-01 | 0.019 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.586682e-01 | 0.018 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.621647e-01 | 0.017 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.623601e-01 | 0.017 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.623601e-01 | 0.017 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.623601e-01 | 0.017 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.623601e-01 | 0.017 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.623601e-01 | 0.017 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.623601e-01 | 0.017 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.630156e-01 | 0.016 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.653762e-01 | 0.015 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.653762e-01 | 0.015 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.653762e-01 | 0.015 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.653762e-01 | 0.015 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.661424e-01 | 0.015 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.661424e-01 | 0.015 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.661424e-01 | 0.015 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.661424e-01 | 0.015 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.675650e-01 | 0.014 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.683245e-01 | 0.014 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.683245e-01 | 0.014 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.684327e-01 | 0.014 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.684327e-01 | 0.014 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.684327e-01 | 0.014 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 9.689744e-01 | 0.014 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.695449e-01 | 0.013 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 9.695449e-01 | 0.013 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.695449e-01 | 0.013 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.695449e-01 | 0.013 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.695449e-01 | 0.013 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.695449e-01 | 0.013 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.695449e-01 | 0.013 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 9.695449e-01 | 0.013 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.695449e-01 | 0.013 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 9.700510e-01 | 0.013 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.710302e-01 | 0.013 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.723559e-01 | 0.012 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.723559e-01 | 0.012 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.726056e-01 | 0.012 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.726056e-01 | 0.012 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 9.726056e-01 | 0.012 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 9.726056e-01 | 0.012 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 9.734553e-01 | 0.012 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.735122e-01 | 0.012 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.742309e-01 | 0.011 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.742404e-01 | 0.011 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.744919e-01 | 0.011 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.744919e-01 | 0.011 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.753588e-01 | 0.011 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.753588e-01 | 0.011 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.757881e-01 | 0.011 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 9.762275e-01 | 0.010 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 9.764706e-01 | 0.010 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.776145e-01 | 0.010 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 9.778355e-01 | 0.010 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.778355e-01 | 0.010 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.778355e-01 | 0.010 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.783026e-01 | 0.010 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.791389e-01 | 0.009 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.797858e-01 | 0.009 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.815368e-01 | 0.008 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 9.815669e-01 | 0.008 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 9.815669e-01 | 0.008 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.827507e-01 | 0.008 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 9.830176e-01 | 0.007 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.833818e-01 | 0.007 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.838702e-01 | 0.007 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.838702e-01 | 0.007 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.846079e-01 | 0.007 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.846079e-01 | 0.007 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.854918e-01 | 0.006 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.854918e-01 | 0.006 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.859510e-01 | 0.006 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 9.869505e-01 | 0.006 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.869505e-01 | 0.006 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 9.869505e-01 | 0.006 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 9.869505e-01 | 0.006 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.871797e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.882626e-01 | 0.005 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.882626e-01 | 0.005 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.882626e-01 | 0.005 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.883035e-01 | 0.005 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.894428e-01 | 0.005 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.896756e-01 | 0.005 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.901587e-01 | 0.004 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.902702e-01 | 0.004 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.905044e-01 | 0.004 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.905044e-01 | 0.004 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.905364e-01 | 0.004 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.909226e-01 | 0.004 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.911284e-01 | 0.004 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.912721e-01 | 0.004 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.914593e-01 | 0.004 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.914593e-01 | 0.004 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.915926e-01 | 0.004 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.919126e-01 | 0.004 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.923183e-01 | 0.003 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.926064e-01 | 0.003 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.926287e-01 | 0.003 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.930909e-01 | 0.003 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.930957e-01 | 0.003 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.931246e-01 | 0.003 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.936336e-01 | 0.003 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.937858e-01 | 0.003 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.942889e-01 | 0.002 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.944109e-01 | 0.002 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.944109e-01 | 0.002 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.944109e-01 | 0.002 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.944109e-01 | 0.002 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.944247e-01 | 0.002 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.951231e-01 | 0.002 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.951238e-01 | 0.002 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 9.951510e-01 | 0.002 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.954788e-01 | 0.002 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.959337e-01 | 0.002 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.963428e-01 | 0.002 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.967108e-01 | 0.001 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.967108e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.973394e-01 | 0.001 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.973394e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.976072e-01 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.976072e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.976086e-01 | 0.001 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.977054e-01 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.977207e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.978249e-01 | 0.001 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.978249e-01 | 0.001 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.978249e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.978480e-01 | 0.001 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.980218e-01 | 0.001 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.980646e-01 | 0.001 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.980974e-01 | 0.001 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.982012e-01 | 0.001 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.985489e-01 | 0.001 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.985922e-01 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.988106e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.988923e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.989398e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.989760e-01 | 0.000 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.989791e-01 | 0.000 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.990000e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.991111e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.991628e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.991718e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.992980e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.993036e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.993302e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.993302e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.993727e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.994822e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.995129e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid biosynthesis | R-HSA-9840309 | 9.995129e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.995737e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.996201e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.996458e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.996458e-01 | 0.000 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.996458e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.997424e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997684e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.998041e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.998538e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.998591e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998760e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.998762e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998798e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.998809e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.998899e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999010e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999264e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999289e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999409e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999527e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999577e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999631e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999768e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999819e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.999821e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.999838e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999854e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999925e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999935e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999938e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999949e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999955e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999957e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999959e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999961e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999963e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999968e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999970e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999972e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999986e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999986e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999988e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999989e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999994e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999998e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999998e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999999e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |